Purification	O
and	O
characterization	O
of	O
the	O
human	B-protein
SR	I-protein
31747A-binding	I-protein
protein	I-protein
.	O

A	O
nuclear	B-protein
membrane	I-protein
protein	I-protein
related	O
to	O
yeast	B-protein
sterol	I-protein
isomerase	I-protein
.	O

SR	O
31747A	O
,	O
defined	O
as	O
a	O
sigma	O
ligand	O
,	O
is	O
a	O
novel	O
immunosuppressive	O
agent	O
that	O
blocks	O
proliferation	O
of	O
human	B-cell_type
and	I-cell_type
mouse	I-cell_type
lymphocytes	I-cell_type
.	O

Using	O
a	O
radiolabeled	O
chemical	O
probe	O
,	O
we	O
here	O
purified	O
a	O
target	O
of	O
SR	O
31747A	O
and	O
called	O
it	O
SR	B-protein
31747A-binding	I-protein
protein	I-protein
(	O
SR-BP	B-protein
)	O
.	O

Purified	B-protein
SR-BP	I-protein
retained	O
its	O
binding	O
properties	O
and	O
migrated	O
on	O
SDS-polyacrylamide	O
gel	O
as	O
a	O
Mr	B-protein
28	I-protein
,	I-protein
000	I-protein
protein	I-protein
.	O

Cloning	O
of	O
the	O
cDNA	B-DNA
encoding	O
human	B-protein
SR-BP	I-protein
shows	O
an	O
open	B-DNA
reading	I-DNA
frame	I-DNA
for	O
a	O
223-amino	B-protein
acid	I-protein
protein	I-protein
,	O
which	O
is	O
homologous	O
to	O
the	O
recently	O
cloned	O
sigma	B-protein
1	I-protein
receptor	I-protein
.	O

Interestingly	O
,	O
the	O
deduced	O
amino	O
acid	O
sequence	O
was	O
found	O
to	O
be	O
related	O
to	O
fungal	B-protein
C8-C7	I-protein
sterol	I-protein
isomerase	I-protein
,	O
encoded	O
by	O
the	O
ERG2	B-DNA
gene	I-DNA
.	O

The	O
ERG2	B-protein
gene	I-protein
product	I-protein
has	O
been	O
identified	O
recently	O
as	O
the	O
molecular	O
target	O
of	O
SR	O
31747A	O
that	O
mediates	O
antiproliferative	O
effects	O
of	O
the	O
drug	O
in	O
yeast	O
.	O

Northern	O
blot	O
analysis	O
of	O
SR-BP	B-protein
gene	O
expression	O
revealed	O
a	O
single	O
transcript	O
of	O
2	B-RNA
kilobases	I-RNA
which	O
was	O
widely	O
expressed	O
among	O
organs	O
,	O
with	O
the	O
highest	O
abundance	O
in	O
liver	O
and	O
the	O
lowest	O
abundance	O
in	O
brain	O
.	O

Subcellular	O
localization	O
analysis	O
in	O
various	O
cells	O
,	O
using	O
a	O
specific	B-protein
monoclonal	I-protein
antibody	I-protein
raised	O
against	O
SR-BP	B-protein
,	O
demonstrated	O
that	O
this	O
protein	O
was	O
associated	O
with	O
the	O
nuclear	O
envelope	O
.	O

When	O
studying	O
the	O
binding	O
of	O
SR	O
31747A	O
on	O
membranes	O
from	O
yeast	O
expressing	O
SR-BP	B-protein
,	O
we	O
found	O
a	O
pharmacological	O
profile	O
of	O
sigma	B-protein
1	I-protein
receptors	I-protein
;	O
binding	O
was	O
displaced	O
by	O
(	O
+	O
)	O
-pentazocine	O
,	O
haloperidol	O
,	O
and	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
,	O
with	O
(	O
+	O
)	O
-SKF	O
10	O
,	O
047	O
being	O
a	O
more	O
potent	O
competitor	O
than	O
(	O
-	O
)	O
-SKF	O
10	O
,	O
047	O
.	O

Scatchard	O
plot	O
analysis	O
revealed	O
Kd	O
values	O
of	O
7.1	O
nM	O
and	O
0.15	O
nM	O
for	O
(	O
+	O
)	O
-pentazocine	O
and	O
SR	O
31747A	O
,	O
respectively	O
,	O
indicating	O
an	O
affinity	O
of	O
SR-BP	B-protein
50-fold	O
higher	O
for	O
SR	O
31747A	O
than	O
for	O
pentazocine	O
.	O

Additionally	O
,	O
we	O
showed	O
that	O
pentazocine	O
,	O
a	O
competitive	O
inhibitor	O
of	O
SR	O
31747A	O
binding	O
,	O
also	O
prevents	O
the	O
immunosuppressive	O
effect	O
of	O
SR	O
31747A	O
.	O

Taken	O
together	O
,	O
these	O
findings	O
strongly	O
suggest	O
that	O
SR-BP	B-protein
represents	O
the	O
molecular	O
target	O
for	O
SR	O
31747A	O
in	O
mammalian	O
tissues	O
,	O
which	O
could	O
be	O
critical	O
for	O
T	O
cell	O
proliferation	O
.	O

THE	NULL
JOURNAL	NULL
or	NULL
BIOLOGICAL	NULL
CHEMISTRY	NULL
©	NULL
1997	NULL
by	NULL
The	NULL
American	NULL
Society	NULL
for	NULL
Biochemistry	NULL
and	NULL
Molecular	NULL
Biology	NULL
,	NULL
Inc.	NULL
Vol	NULL
.	NULL

272	NULL
,	NULL
No	NULL
.	NULL

43	NULL
,	NULL
Issue	NULL
of	NULL
October	NULL
24	NULL
,	NULL
pp	NULL
.	NULL

27107-27115	NULL
,	NULL
1997	NULL
Printed	NULL
in	NULL
U.S.A.	NULL
Purification	NULL
and	NULL
Characterization	NULL
of	NULL
the	NULL
Human	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
A	NULL
NUCLEAR	NULL
MEMBRANE	NULL
PROTEIN	NULL
RELATED	NULL
TO	NULL
YEAST	NULL
STEROL	NULL
ISOMERASE*	NULL
(	NULL
Received	NULL
for	NULL
publication	NULL
,	NULL
June	NULL
19	NULL
,	NULL
1997	NULL
,	NULL
and	NULL
in	NULL
revised	NULL
form	NULL
,	NULL
August	NULL
13	NULL
,	NULL
1997	NULL
)	NULL
Omar	NULL
Jbilo	NULL
$	NULL
§	NULL
,	NULL
Hubert	NULL
Raymond	NULL
Paul	NULL
}	NULL
,	NULL
Nathalie	NULL
De	NULL
Nys	NULL
#	NULL
,	NULL
Mohammed	NULL
Bensaid	NULL
$	NULL
,	NULL
Sandra	NULL
Silve1	NULL
,	NULL
Pierre	NULL
Carayont	NULL
,	NULL
Danielle	NULL
Davi	NULL
}	NULL
,	NULL
Sylvaine	NULL
Galiéguet	NULL
,	NULL
Bernard	NULL
Bourrié	NULL
}	NULL
,	NULL
Jean-Claude	NULL
Guillemot	NULL
]	NULL
,	NULL
Pascual	NULL
Ferrarat	NULL
,	NULL
Gérard	NULL
Loison1	NULL
,	NULL
Jean-Pierre	NULL
Maffrand	NULL
]	NULL
,	NULL
Gérard	NULL
Le	NULL
Fur**	NULL
,	NULL
and	NULL
Pierre	NULL
Casellast	NULL
$	NULL
#	NULL
From	NULL
{	NULL
Sanofi	NULL
,	NULL
371	NULL
rue	NULL
du	NULL
Pr	NULL
.	NULL

Joseph	NULL
Blayac	NULL
,	NULL
34184	NULL
Montpellier	NULL
cedex	NULL
04	NULL
,	NULL
Sanofi	NULL
,	NULL
Voie	NULL
no	NULL
.	NULL

1	NULL
,	NULL
BP	NULL
137	NULL
,	NULL
31676	NULL
Labége	NULL
cedex	NULL
,	NULL
Sanofi	NULL
,	NULL
195	NULL
route	NULL
d'Espagne	NULL
,	NULL
31036	NULL
Toulouse	NULL
cedex	NULL
,	NULL
and	NULL
**Sanofi	NULL
,	NULL
32-34	NULL
rue	NULL
Marbeuf	NULL
,	NULL
75374	NULL
Paris	NULL
cedex	NULL
08	NULL
,	NULL
France	NULL
SR	NULL
31747	NULL
,	NULL
defined	NULL
as	NULL
a	NULL
sigma	NULL
ligand	NULL
,	NULL
is	NULL
a	NULL
novel	NULL
immunosuppressive	NULL
agent	NULL
that	NULL
blocks	NULL
proliferation	NULL
of	NULL
human	NULL
and	NULL
mouse	NULL
lymphocytes	NULL
.	NULL

Using	NULL
a	NULL
radiolabeled	NULL
chemical	NULL
probe	NULL
,	NULL
we	NULL
here	NULL
purified	NULL
a	NULL
target	NULL
of	NULL
SR	NULL
31747A	NULL
and	NULL
called	NULL
it	NULL
SR	NULL
31747A-binding	NULL
protein	NULL
(	NULL
SR-BP	NULL
)	NULL
.	NULL

Purified	NULL
SR-BP	NULL
retained	NULL
its	NULL
binding	NULL
properties	NULL
and	NULL
migrated	NULL
on	NULL
SDS-polyacrylamide	NULL
gel	NULL
as	NULL
a	NULL
M	NULL
,	NULL
,	NULL
28,000	NULL
protein	NULL
.	NULL

Cloning	NULL
of	NULL
the	NULL
cDNA	NULL
encoding	NULL
human	NULL
SR-BP	NULL
shows	NULL
an	NULL
open	NULL
reading	NULL
frame	NULL
for	NULL
a	NULL
223-amino	NULL
acid	NULL
protein	NULL
,	NULL
which	NULL
is	NULL
homologous	NULL
to	NULL
the	NULL
recently	NULL
cloned	NULL
sigma	NULL
1	NULL
receptor	NULL
.	NULL

Interestingly	NULL
,	NULL
the	NULL
deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
was	NULL
found	NULL
to	NULL
be	NULL
related	NULL
to	NULL
fungal	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
,	NULL
encoded	NULL
by	NULL
the	NULL
ERG2	NULL
gene	NULL
.	NULL

The	NULL
ERG2	NULL
gene	NULL
product	NULL
has	NULL
been	NULL
identified	NULL
recently	NULL
as	NULL
the	NULL
molecular	NULL
target	NULL
of	NULL
SR	NULL
31747A	NULL
that	NULL
mediates	NULL
antiproliferative	NULL
effects	NULL
of	NULL
the	NULL
drug	NULL
in	NULL
yeast	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
SR-BP	NULL
gene	NULL
expression	NULL
revealed	NULL
a	NULL
single	NULL
transcript	NULL
of	NULL
2	NULL
kilobases	NULL
which	NULL
was	NULL
widely	NULL
expressed	NULL
among	NULL
organs	NULL
,	NULL
with	NULL
the	NULL
highest	NULL
abundance	NULL
in	NULL
liver	NULL
and	NULL
the	NULL
lowest	NULL
abundance	NULL
in	NULL
brain	NULL
.	NULL

Subcellular	NULL
localization	NULL
analysis	NULL
in	NULL
various	NULL
cells	NULL
,	NULL
using	NULL
a	NULL
specific	NULL
monoclonal	NULL
antibody	NULL
raised	NULL
against	NULL
SR-BP	NULL
,	NULL
demonstrated	NULL
that	NULL
this	NULL
protein	NULL
was	NULL
associated	NULL
with	NULL
the	NULL
nuclear	NULL
envelope	NULL
.	NULL

When	NULL
studying	NULL
the	NULL
binding	NULL
of	NULL
SR	NULL
31747A	NULL
on	NULL
membranes	NULL
from	NULL
yeast	NULL
expressing	NULL
SR-BP	NULL
,	NULL
we	NULL
found	NULL
a	NULL
pharmacological	NULL
profile	NULL
of	NULL
sigma	NULL
1	NULL
receptors	NULL
;	NULL
binding	NULL
was	NULL
displaced	NULL
by	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
,	NULL
haloperidol	NULL
,	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-SKF	NULL
10,047	NULL
,	NULL
with	NULL
(	NULL
+	NULL
)	NULL
-SKF	NULL
10,047	NULL
being	NULL
a	NULL
more	NULL
potent	NULL
competitor	NULL
than	NULL
(	NULL
-	NULL
)	NULL
-SKF	NULL
10,047	NULL
.	NULL

Scatchard	NULL
plot	NULL
analysis	NULL
revealed	NULL
K	NULL
,	NULL
values	NULL
of	NULL
7.1	NULL
nm	NULL
and	NULL
0.15	NULL
nm	NULL
for	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
and	NULL
SR	NULL
31747	NULL
,	NULL
respectively	NULL
,	NULL
indicating	NULL
an	NULL
affinity	NULL
of	NULL
SR-BP	NULL
50-fold	NULL
higher	NULL
for	NULL
SR	NULL
31747	NULL
than	NULL
for	NULL
pentazocine	NULL
.	NULL

Additionally	NULL
,	NULL
we	NULL
showed	NULL
that	NULL
pentazocine	NULL
,	NULL
a	NULL
competitive	NULL
inhibitor	NULL
of	NULL
SR	NULL
31747A	NULL
binding	NULL
,	NULL
also	NULL
prevents	NULL
the	NULL
immunosuppressive	NULL
effect	NULL
of	NULL
SR	NULL
31747A	NULL
.	NULL

Taken	NULL
together	NULL
,	NULL
these	NULL
findings	NULL
strongly	NULL
suggest	NULL
that	NULL
SR-BP	NULL
represents	NULL
the	NULL
molecular	NULL
target	NULL
for	NULL
SR	NULL
317474	NULL
in	NULL
mammalian	NULL
tissues	NULL
,	NULL
which	NULL
could	NULL
be	NULL
critical	NULL
for	NULL
T	NULL
cell	NULL
proliferation	NULL
.	NULL

*	NULL
The	NULL
costs	NULL
of	NULL
publication	NULL
of	NULL
this	NULL
article	NULL
were	NULL
defrayed	NULL
in	NULL
part	NULL
by	NULL
the	NULL
payment	NULL
of	NULL
page	NULL
charges	NULL
.	NULL

This	NULL
article	NULL
must	NULL
therefore	NULL
be	NULL
hereby	NULL
marked	NULL
``	NULL
advertisement	NULL
``	NULL
in	NULL
accordance	NULL
with	NULL
18	NULL
U.S.C	NULL
.	NULL

Section	NULL
1734	NULL
solely	NULL
to	NULL
indicate	NULL
this	NULL
fact	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
(	NULL
s	NULL
)	NULL
reported	NULL
in	NULL
this	NULL
paper	NULL
has	NULL
been	NULL
submitted	NULL
to	NULL
the	NULL
GenBank	NULL
``	NULL
/EBI	NULL
Data	NULL
Bank	NULL
with	NULL
accession	NULL
number	NULL
(	NULL
s	NULL
)	NULL
U79528	NULL
.	NULL

§	NULL
Both	NULL
authors	NULL
contributed	NULL
equally	NULL
to	NULL
this	NULL
work	NULL
.	NULL

{	NULL
}	NULL
To	NULL
whom	NULL
correspondence	NULL
should	NULL
be	NULL
addressed	NULL
:	NULL
Tel	NULL
.	NULL

:	NULL
383-4-67-10-62-90	NULL
;	NULL
Fax	NULL
:	NULL
38-4-67-10-68-83	NULL
;	NULL
e-mail	NULL
:	NULL
pierre.casellas	NULL
@	NULL
tls1.elfsanofi.fr	NULL
.	NULL

This	NULL
paper	NULL
is	NULL
available	NULL
on	NULL
line	NULL
at	NULL
http	NULL
:	NULL
//www.jbc.org	NULL
Sigma	NULL
receptors	NULL
,	NULL
initially	NULL
identified	NULL
by	NULL
Martin	NULL
et	NULL
al	NULL
.	NULL

(	NULL
1	NULL
)	NULL
as	NULL
a	NULL
subclass	NULL
of	NULL
opiate	NULL
receptors	NULL
,	NULL
were	NULL
characterized	NULL
by	NULL
Su	NULL
(	NULL
2	NULL
,	NULL
3	NULL
)	NULL
in	NULL
guinea	NULL
pig	NULL
brain	NULL
.	NULL

They	NULL
were	NULL
subsequently	NULL
found	NULL
to	NULL
be	NULL
distributed	NULL
in	NULL
a	NULL
variety	NULL
of	NULL
distinct	NULL
regions	NULL
of	NULL
the	NULL
central	NULL
nervous	NULL
system	NULL
(	NULL
4	NULL
)	NULL
,	NULL
as	NULL
well	NULL
as	NULL
in	NULL
endocrine-related	NULL
structures	NULL
(	NULL
5	NULL
)	NULL
,	NULL
gastrointestinal	NULL
tract	NULL
(	NULL
6	NULL
)	NULL
,	NULL
liver	NULL
(	NULL
7	NULL
)	NULL
,	NULL
and	NULL
kidney	NULL
(	NULL
8	NULL
)	NULL
.	NULL

Sigma	NULL
receptors	NULL
were	NULL
further	NULL
identified	NULL
in	NULL
human	NULL
peripheral	NULL
blood	NULL
mononu-clear	NULL
cells	NULL
(	NULL
9-12	NULL
)	NULL
,	NULL
and	NULL
their	NULL
presence	NULL
was	NULL
confirmed	NULL
in	NULL
rat	NULL
spleen	NULL
.	NULL

The	NULL
biological	NULL
significance	NULL
of	NULL
sigma	NULL
receptors	NULL
in	NULL
the	NULL
immune	NULL
system	NULL
is	NULL
poorly	NULL
understood	NULL
.	NULL

However	NULL
,	NULL
Liu	NULL
et	NULL
al	NULL
.	NULL

(	NULL
12	NULL
)	NULL
,	NULL
using	NULL
a	NULL
panel	NULL
of	NULL
sigma	NULL
ligands	NULL
,	NULL
demonstrated	NULL
a	NULL
high	NULL
correlation	NULL
between	NULL
drug	NULL
binding	NULL
potency	NULL
at	NULL
sigma	NULL
sites	NULL
and	NULL
inhibition	NULL
of	NULL
splenocyte	NULL
proliferation	NULL
,	NULL
suggesting	NULL
that	NULL
sigma	NULL
receptors	NULL
may	NULL
function	NULL
as	NULL
immunoregulators	NULL
.	NULL

SR	NULL
31747A	NULL
was	NULL
first	NULL
described	NULL
by	NULL
Paul	NULL
et	NULL
al	NULL
.	NULL

(	NULL
13	NULL
)	NULL
as	NULL
a	NULL
ligand	NULL
able	NULL
to	NULL
compete	NULL
with	NULL
a	NULL
very	NULL
high	NULL
potency	NULL
with	NULL
all	NULL
known	NULL
sigma	NULL
ligands	NULL
and	NULL
to	NULL
inhibit	NULL
mitogen-induced	NULL
mouse	NULL
and	NULL
human	NULL
T	NULL
cell	NULL
proliferation	NULL
with	NULL
a	NULL
potency	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
cyclosporin	NULL
A	NULL
(	NULL
14	NULL
)	NULL
.	NULL

However	NULL
,	NULL
unlike	NULL
cyclosporin	NULL
A	NULL
,	NULL
SR	NULL
31747A	NULL
does	NULL
not	NULL
alter	NULL
early	NULL
cellular	NULL
events	NULL
,	NULL
but	NULL
rather	NULL
interferes	NULL
at	NULL
steps	NULL
further	NULL
along	NULL
the	NULL
pathway	NULL
leading	NULL
to	NULL
proliferation	NULL
,	NULL
most	NULL
probably	NULL
during	NULL
the	NULL
S	NULL
phase	NULL
(	NULL
14	NULL
)	NULL
.	NULL

Multiple	NULL
receptors	NULL
have	NULL
been	NULL
described	NULL
(	NULL
8	NULL
,	NULL
15-19	NULL
)	NULL
.	NULL

Sigma	NULL
1	NULL
designates	NULL
a	NULL
high	NULL
affinity	NULL
binding	NULL
site	NULL
,	NULL
which	NULL
is	NULL
stereoselective	NULL
for	NULL
(	NULL
+	NULL
)	NULL
-optical	NULL
enantiomers	NULL
of	NULL
pentazocine	NULL
,	NULL
SKF	NULL
10,047	NULL
,	NULL
and	NULL
3-	NULL
(	NULL
8-hydroxyphenyl	NULL
)	NULL
-N-	NULL
(	NULL
1-propyl	NULL
)	NULL
-piperidine	NULL
(	NULL
3-PPP	NULL
)	NULL
.	NULL

*	NULL
Sigma	NULL
2	NULL
refers	NULL
to	NULL
a	NULL
site	NULL
that	NULL
binds	NULL
these	NULL
drugs	NULL
with	NULL
lower	NULL
affinity	NULL
,	NULL
and	NULL
which	NULL
is	NULL
selective	NULL
for	NULL
(	NULL
-	NULL
)	NULL
-optical	NULL
enantiomers	NULL
of	NULL
pentazocine	NULL
,	NULL
SKF	NULL
10,047	NULL
,	NULL
and	NULL
3-PPP	NULL
.	NULL

A	NULL
lower	NULL
affinity	NULL
sigma	NULL
3	NULL
site	NULL
has	NULL
been	NULL
reported	NULL
in	NULL
rat	NULL
and	NULL
guinea	NULL
pig	NULL
brain	NULL
(	NULL
20	NULL
)	NULL
.	NULL

More	NULL
recently	NULL
,	NULL
a	NULL
novel	NULL
binding	NULL
site	NULL
was	NULL
discovered	NULL
that	NULL
binds	NULL
all	NULL
sigma	NULL
ligands	NULL
with	NULL
two	NULL
notable	NULL
exceptions	NULL
:	NULL
haloperidol	NULL
and	NULL
1,3-di	NULL
(	NULL
2-tolyl	NULL
)	NULL
guani-dine	NULL
(	NULL
21	NULL
,	NULL
22	NULL
)	NULL
.	NULL

Pharmacological	NULL
studies	NULL
with	NULL
SR	NULL
31747	NULL
can	NULL
not	NULL
discriminate	NULL
among	NULL
sigma	NULL
1	NULL
,	NULL
sigma	NULL
2	NULL
,	NULL
sigma	NULL
3	NULL
,	NULL
and	NULL
the	NULL
novel	NULL
sigma/	NULL
opioid	NULL
binding	NULL
sites	NULL
since	NULL
multiple	NULL
types	NULL
of	NULL
sigma	NULL
receptors	NULL
can	NULL
coexist	NULL
on	NULL
cells	NULL
(	NULL
19	NULL
)	NULL
.	NULL

Moreover	NULL
,	NULL
the	NULL
cross-reactivity	NULL
of	NULL
many	NULL
drugs	NULL
that	NULL
bind	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
other	NULL
receptors	NULL
has	NULL
impeded	NULL
efforts	NULL
to	NULL
define	NULL
precisely	NULL
the	NULL
sites	NULL
for	NULL
SR	NULL
31747A	NULL
binding	NULL
.	NULL

Recently	NULL
,	NULL
we	NULL
examined	NULL
the	NULL
effect	NULL
of	NULL
this	NULL
drug	NULL
in	NULL
the	NULL
yeast	NULL
*	NULL
The	NULL
abbreviations	NULL
used	NULL
are	NULL
:	NULL
8-PPP	NULL
,	NULL
8-	NULL
(	NULL
8-hydroxyphenyl	NULL
)	NULL
-N-	NULL
(	NULL
1-pro-pyl	NULL
)	NULL
-piperidine	NULL
;	NULL
mAb	NULL
,	NULL
monoclonal	NULL
antibody	NULL
;	NULL
SR-BP	NULL
,	NULL
SR	NULL
31747A-binding	NULL
protein	NULL
;	NULL
BSA	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
;	NULL
RACE	NULL
,	NULL
rapid	NULL
amplification	NULL
of	NULL
cDNA	NULL
end	NULL
;	NULL
PCR	NULL
,	NULL
polymerase	NULL
chain	NULL
reaction	NULL
;	NULL
PBS	NULL
,	NULL
phosphate-buffered	NULL
saline	NULL
;	NULL
SKF	NULL
10,047	NULL
,	NULL
norallylmetazocine	NULL
;	NULL
PAGE	NULL
,	NULL
polyacrylamide	NULL
gel	NULL
elec-trophresis	NULL
;	NULL
bp	NULL
,	NULL
base	NULL
pair	NULL
(	NULL
s	NULL
)	NULL
.	NULL

27107	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
27108	NULL
Saccharomyces	NULL
cerevisiae	NULL
.	NULL

We	NULL
showed	NULL
that	NULL
SR	NULL
31747	NULL
arrested	NULL
cell	NULL
proliferation	NULL
by	NULL
inhibiting	NULL
an	NULL
enzyme	NULL
of	NULL
the	NULL
sterol	NULL
biosyn-thetic	NULL
pathway	NULL
,	NULL
namely	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
(	NULL
23	NULL
)	NULL
.	NULL

In	NULL
the	NULL
present	NULL
work	NULL
,	NULL
we	NULL
undertook	NULL
a	NULL
biochemical	NULL
characterization	NULL
of	NULL
a	NULL
molecular	NULL
entity	NULL
that	NULL
specifically	NULL
binds	NULL
SR	NULL
31747A	NULL
using	NULL
[	NULL
°PHJSR	NULL
31747A	NULL
as	NULL
the	NULL
specific	NULL
probe	NULL
and	NULL
the	NULL
human	NULL
T	NULL
leukemia	NULL
cell	NULL
line	NULL
Ichikawa	NULL
as	NULL
the	NULL
biological	NULL
source	NULL
.	NULL

We	NULL
purified	NULL
the	NULL
protein	NULL
carrying	NULL
the	NULL
SR	NULL
31747A	NULL
binding	NULL
site	NULL
and	NULL
cloned	NULL
the	NULL
corresponding	NULL
cDNA	NULL
,	NULL
which	NULL
was	NULL
shown	NULL
to	NULL
be	NULL
homologous	NULL
to	NULL
the	NULL
yeast	NULL
ERG2	NULL
gene	NULL
.	NULL

Expression	NULL
of	NULL
SR-BP	NULL
cDNA	NULL
in	NULL
yeast	NULL
S.	NULL
cerevisiae	NULL
led	NULL
to	NULL
high	NULL
affinity	NULL
binding	NULL
sites	NULL
for	NULL
SR	NULL
31747A	NULL
indistinguishable	NULL
from	NULL
mammalian	NULL
sites	NULL
.	NULL

We	NULL
also	NULL
present	NULL
the	NULL
tissue	NULL
distribution	NULL
and	NULL
subcellular	NULL
localization	NULL
and	NULL
discuss	NULL
the	NULL
structural	NULL
features	NULL
of	NULL
this	NULL
receptor	NULL
and	NULL
its	NULL
possible	NULL
functions	NULL
.	NULL

MATERIALS	NULL
AND	NULL
METHODS	NULL
Reagents	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-Pentazocine	NULL
(	NULL
NET	NULL
1056-1550	NULL
GBq/mmol	NULL
)	NULL
was	NULL
supplied	NULL
by	NULL
NEN	NULL
Life	NULL
Science	NULL
Products	NULL
(	NULL
Paris	NULL
,	NULL
France	NULL
)	NULL
.	NULL

SR	NULL
81747	NULL
,	NULL
(	NULL
Z	NULL
)	NULL
-N-cyclo-hexyl-N-ethyl-3-	NULL
(	NULL
8-chloro-4-cyclohexylphenyl	NULL
)	NULL
-propen-2-ylamine	NULL
hydro-chloride	NULL
,	NULL
and	NULL
[	NULL
°HJSR	NULL
317474	NULL
(	NULL
2109	NULL
GBq/mmo	NULL
!	NULL
)	NULL

were	NULL
synthetized	NULL
by	NULL
Sanofi	NULL
Recherche	NULL
.	NULL

1,8-di	NULL
(	NULL
2-tolyl	NULL
)	NULL
guanidine	NULL
,	NULL
(	NULL
+	NULL
)	NULL
-8-PPP	NULL
,	NULL
(	NULL
-	NULL
)	NULL
-8-PPP	NULL
,	NULL
(	NULL
+	NULL
)	NULL
-SKF	NULL
10,047	NULL
,	NULL
(	NULL
-	NULL
)	NULL
-SKF	NULL
10,047	NULL
,	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-	NULL
and	NULL
(	NULL
-	NULL
)	NULL
-pentazocine	NULL
were	NULL
supplied	NULL
by	NULL
Research	NULL
Biochemicals	NULL
Inc.	NULL
(	NULL
Natick	NULL
,	NULL
MA	NULL
)	NULL
.	NULL

Digitonin	NULL
,	NULL
haloperidol	NULL
,	NULL
ifenprodil	NULL
,	NULL
and	NULL
the	NULL
anti-bleaching	NULL
reagent	NULL
DABCO	NULL
were	NULL
supplied	NULL
by	NULL
Sigma	NULL
.	NULL

Fenpropimorph	NULL
and	NULL
tridemorph	NULL
were	NULL
a	NULL
generous	NULL
gift	NULL
of	NULL
Dr.	NULL
A.	NULL
Akers	NULL
(	NULL
BASF	NULL
Aktiengesellshaft	NULL
,	NULL
Limburgerhof	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

LH,0	NULL
,	NULL
DEAE-Sepharose	NULL
,	NULL
Mono	NULL
Q	NULL
HR	NULL
10/10	NULL
,	NULL
Superdex	NULL
200	NULL
HR	NULL
,	NULL
and	NULL
CNBr-Sepharose	NULL
4B	NULL
were	NULL
purchased	NULL
from	NULL
Pharmacia	NULL
(	NULL
Orsay	NULL
,	NULL
France	NULL
)	NULL
.	NULL

Q	NULL
Hyper	NULL
D	NULL
column	NULL
was	NULL
from	NULL
Biosepra	NULL
(	NULL
Frankfurt	NULL
,	NULL
Germany	NULL
)	NULL
.	NULL

Strains	NULL
,	NULL
Media	NULL
,	NULL
and	NULL
Growth	NULL
Conditions	NULL
EMY43	NULL
(	NULL
MATa	NULL
,	NULL
ura3A	NULL
,	NULL
trpl-4	NULL
,	NULL
erg2=TRP1	NULL
)	NULL
and	NULL
EMY47	NULL
(	NULL
MATa	NULL
,	NULL
ura3A	NULL
,	NULL
trpl-4	NULL
,	NULL
erg2	NULL
:	NULL
TRP1	NULL
,	NULL
fen1	NULL
:	NULL
:	NULL
LEU2	NULL
)	NULL
were	NULL
isogenic	NULL
derivatives	NULL
of	NULL
S.	NULL
cerevisiae	NULL
wild	NULL
type	NULL
FL100	NULL
(	NULL
ATCC-28383	NULL
)	NULL
.	NULL

C18-ABYS86	NULL
(	NULL
EMYT761	NULL
,	NULL
MATa	NULL
,	NULL
ura3A5	NULL
leu2-3	NULL
leu2-112	NULL
his3	NULL
pral	NULL
prb1	NULL
prel	NULL
eps1	NULL
)	NULL
was	NULL
kindly	NULL
provided	NULL
by	NULL
Heinemeyer	NULL
et	NULL
al	NULL
.	NULL

(	NULL
24	NULL
)	NULL
.	NULL

Yeast	NULL
culture	NULL
media	NULL
were	NULL
YPD	NULL
medium	NULL
and	NULL
synthetic	NULL
minimal	NULL
(	NULL
SD	NULL
)	NULL
medium	NULL
containing	NULL
2	NULL
%	NULL
glucose	NULL
(	NULL
25	NULL
)	NULL
.	NULL

Anaerobic	NULL
conditions	NULL
were	NULL
obtained	NULL
using	NULL
an	NULL
anaerobic	NULL
glove	NULL
box	NULL
(	NULL
La	NULL
Calhéne	NULL
,	NULL
Vélizy	NULL
,	NULL
France	NULL
)	NULL
under	NULL
N	NULL
,	NULL
-H	NULL
,	NULL
-CO	NULL
,	NULL
(	NULL
85-10	NULL
%	NULL
-5	NULL
%	NULL
)	NULL
atmo-sphere	NULL
.	NULL

For	NULL
anaerobic	NULL
growth	NULL
,	NULL
media	NULL
were	NULL
supplemented	NULL
with	NULL
0.1	NULL
%	NULL
Tween	NULL
80	NULL
and	NULL
50	NULL
mg/liter	NULL
ergosterol	NULL
.	NULL

Drug	NULL
Binding	NULL
Assay	NULL
SR	NULL
31747A	NULL
Binding	NULL
Assays	NULL
on	NULL
Soluble	NULL
Receptor-To	NULL
monitor	NULL
SR	NULL
31747A	NULL
binding	NULL
activity	NULL
during	NULL
the	NULL
purification	NULL
process	NULL
,	NULL
a	NULL
SR	NULL
81747A	NULL
binding	NULL
assay	NULL
on	NULL
soluble	NULL
receptor	NULL
was	NULL
developed	NULL
.	NULL

Briefly	NULL
,	NULL
2	NULL
nM	NULL
[	NULL
°HJSR	NULL
31747A	NULL
was	NULL
incubated	NULL
with	NULL
10	NULL
to	NULL
50	NULL
ul	NULL
of	NULL
each	NULL
fraction	NULL
in	NULL
a	NULL
final	NULL
volume	NULL
of	NULL
250	NULL
ul	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
0.1	NULL
%	NULL
BSA	NULL
for	NULL
30	NULL
min	NULL
at	NULL
20	NULL
°C	NULL
.	NULL

Separation	NULL
of	NULL
bound	NULL
from	NULL
free	NULL
ligands	NULL
was	NULL
obtained	NULL
by	NULL
gel	NULL
filtration	NULL
with	NULL
a	NULL
l-ml	NULL
LH	NULL
20	NULL
column	NULL
.	NULL

Samples	NULL
(	NULL
200	NULL
ul	NULL
)	NULL
were	NULL
loaded	NULL
onto	NULL
the	NULL
column	NULL
and	NULL
eluted	NULL
with	NULL
1.8	NULL
ml	NULL
of	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
.	NULL

The	NULL
2-ml	NULL
volume	NULL
containing	NULL
bound	NULL
[	NULL
°HJSR	NULL
31747A	NULL
was	NULL
mixed	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
scintillation	NULL
liquid	NULL
and	NULL
counted	NULL
for	NULL
radioactivity	NULL
.	NULL

In	NULL
competition	NULL
studies	NULL
using	NULL
purified	NULL
receptor	NULL
,	NULL
various	NULL
concentrations	NULL
(	NULL
0.4-1000	NULL
nM	NULL
)	NULL
of	NULL
unlabeled	NULL
ligands	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
20	NULL
°C	NULL
with	NULL
1	NULL
nm	NULL
[	NULL
°HJSR	NULL
31747A	NULL
in	NULL
500	NULL
pl	NULL
of	NULL
binding	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
containing	NULL
0.1	NULL
%	NULL
BSA	NULL
,	NULL
0.02	NULL
%	NULL
digitonin	NULL
,	NULL
0.02	NULL
%	NULL
Tween	NULL
20	NULL
)	NULL
.	NULL

For	NULL
saturation	NULL
analysis	NULL
,	NULL
purified	NULL
receptor	NULL
was	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
20	NULL
°C	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
[	NULL
°HJSR	NULL
31747A	NULL
(	NULL
0.08-8	NULL
nM	NULL
)	NULL
in	NULL
the	NULL
presence	NULL
or	NULL
absence	NULL
of	NULL
1	NULL
uM	NULL
SR	NULL
31747A	NULL
in	NULL
binding	NULL
buffer	NULL
.	NULL

SR	NULL
31747A	NULL
Binding	NULL
Studies	NULL
on	NULL
Yeast	NULL
Cell	NULL
Membranes-Yeast	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
zymolyase	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
26	NULL
)	NULL
and	NULL
homogenized	NULL
at	NULL
4	NULL
°C	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
buffer	NULL
,	NULL
pH	NULL
8.0	NULL
,	NULL
for	NULL
membrane	NULL
prepa-ration	NULL
.	NULL

Receptor	NULL
binding	NULL
assays	NULL
for	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
and	NULL
[	NULL
°HJSR	NULL
31747A	NULL
were	NULL
performed	NULL
according	NULL
to	NULL
the	NULL
methods	NULL
described	NULL
by	NULL
Paul	NULL
et	NULL
al	NULL
.	NULL

(	NULL
18	NULL
)	NULL
.	NULL

Purification	NULL
of	NULL
the	NULL
Human	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
(	NULL
SR-BP	NULL
)	NULL
Human	NULL
T	NULL
leukemia	NULL
Ichikawa	NULL
cells	NULL
(	NULL
2	NULL
X	NULL
10°	NULL
cells	NULL
)	NULL
were	NULL
suspended	NULL
in	NULL
200	NULL
ml	NULL
of	NULL
a	NULL
buffer	NULL
containing	NULL
70	NULL
mM	NULL
sucrose	NULL
,	NULL
210	NULL
mM	NULL
D-mannitol	NULL
,	NULL
2	NULL
mM	NULL
EDTA	NULL
,	NULL
1	NULL
mM	NULL
4-	NULL
(	NULL
2-aminoethyl-1	NULL
)	NULL
-phenylsulfonyl	NULL
fluoride	NULL
,	NULL
and	NULL
2	NULL
mM	NULL
Hepes	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
then	NULL
homogenized	NULL
using	NULL
a	NULL
Turrax	NULL
homogenizer	NULL
.	NULL

The	NULL
crude	NULL
homogenate	NULL
was	NULL
centrifuged	NULL
at	NULL
650	NULL
%	NULL
g	NULL
for	NULL
20	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
further	NULL
centrifuged	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
1	NULL
h.	NULL
The	NULL
mem-	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
brane-containing	NULL
pellet	NULL
was	NULL
solubilized	NULL
at	NULL
10	NULL
mg/ml	NULL
in	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
1	NULL
mM	NULL
4-	NULL
(	NULL
2-aminoethyl-1	NULL
)	NULL
-phenylsulfonyl	NULL
fluoride	NULL
,	NULL
2	NULL
%	NULL
digitonin	NULL
.	NULL

The	NULL
suspension	NULL
was	NULL
centrifuged	NULL
at	NULL
100,000	NULL
x	NULL
g	NULL
for	NULL
30	NULL
min	NULL
,	NULL
and	NULL
the	NULL
supernatant	NULL
was	NULL
then	NULL
subjected	NULL
to	NULL
chromatography	NULL
successively	NULL
on	NULL
DEAE-Sepharose	NULL
column	NULL
(	NULL
2.5	NULL
X	NULL
11	NULL
em	NULL
)	NULL
,	NULL
Mono	NULL
Q	NULL
column	NULL
(	NULL
1	NULL
X	NULL
10	NULL
cm	NULL
)	NULL
,	NULL
Q	NULL
Hyper	NULL
D	NULL
column	NULL
(	NULL
0.5	NULL
X	NULL
10	NULL
cm	NULL
)	NULL
,	NULL
and	NULL
then	NULL
Superdex	NULL
200	NULL
HR	NULL
column	NULL
(	NULL
1	NULL
X	NULL
30	NULL
em	NULL
)	NULL
.	NULL

These	NULL
columns	NULL
were	NULL
pre-equilibrated	NULL
with	NULL
TDG	NULL
buffer	NULL
(	NULL
50	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
and	NULL
0.1	NULL
%	NULL
digitonin	NULL
)	NULL
.	NULL

Bound	NULL
proteins	NULL
were	NULL
eluted	NULL
with	NULL
linear	NULL
NaCl	NULL
gradient	NULL
(	NULL
0-500	NULL
mM	NULL
)	NULL
in	NULL
TDG	NULL
buffer	NULL
.	NULL

Peak	NULL
fractions	NULL
containing	NULL
SR	NULL
81747-binding	NULL
protein	NULL
were	NULL
monitored	NULL
by	NULL
[	NULL
°HJSR	NULL
81747	NULL
binding	NULL
activity	NULL
.	NULL

Purified	NULL
binding	NULL
activity	NULL
from	NULL
200	NULL
HR	NULL
column	NULL
was	NULL
used	NULL
for	NULL
generation	NULL
of	NULL
specific	NULL
antibodies	NULL
as	NULL
described	NULL
below	NULL
.	NULL

To	NULL
immunopurify	NULL
SR-BP	NULL
,	NULL
active	NULL
peak	NULL
from	NULL
the	NULL
DEAE-Sepharose	NULL
was	NULL
loaded	NULL
onto	NULL
a	NULL
2-ml	NULL
column	NULL
of	NULL
anti-SR-BP	NULL
Sepharose	NULL
obtained	NULL
by	NULL
coupling	NULL
purified	NULL
monoclonal	NULL
anti-SR-BP	NULL
antibody	NULL
(	NULL
see	NULL
below	NULL
)	NULL
to	NULL
CNBr-activated	NULL
Sepharose	NULL
(	NULL
ratio	NULL
:	NULL
0.5	NULL
mg	NULL
of	NULL
proteins/ml	NULL
of	NULL
Sepharose	NULL
)	NULL
.	NULL

Bound	NULL
proteins	NULL
were	NULL
eluted	NULL
with	NULL
0.1	NULL
M	NULL
glycine	NULL
pH	NULL
8.0	NULL
,	NULL
0.5	NULL
m	NULL
NaCl	NULL
,	NULL
0.02	NULL
%	NULL
digitonin	NULL
.	NULL

The	NULL
fractions	NULL
containing	NULL
binding	NULL
activity	NULL
were	NULL
neutralized	NULL
to	NULL
pH	NULL
7.0	NULL
with	NULL
1	NULL
M	NULL
Tris-HCl	NULL
and	NULL
concentrated	NULL
for	NULL
further	NULL
analysis	NULL
.	NULL

Anti-SR-BP	NULL
Monoclonal	NULL
Antibody	NULL
Obtention	NULL
Positive	NULL
fractions	NULL
from	NULL
Q	NULL
Hyper	NULL
D	NULL
chromatography	NULL
were	NULL
incubated	NULL
with	NULL
2	NULL
nm	NULL
[	NULL
°HJSR	NULL
31747A	NULL
for	NULL
2	NULL
h	NULL
at	NULL
20°C	NULL
and	NULL
chromatographed	NULL
on	NULL
Superdex	NULL
200	NULL
HR	NULL
as	NULL
described	NULL
above	NULL
.	NULL

Fractions	NULL
containing	NULL
the	NULL
maximum	NULL
radioactivity	NULL
were	NULL
pooled	NULL
and	NULL
used	NULL
as	NULL
tritiated	NULL
SR-BP	NULL
(	NULL
[	NULL
PHJSR-BP	NULL
)	NULL
for	NULL
antibody	NULL
screening	NULL
.	NULL

Three	NULL
mice	NULL
were	NULL
immunized	NULL
by	NULL
subcutaneous	NULL
injection	NULL
of	NULL
10	NULL
ug	NULL
of	NULL
proteins	NULL
of	NULL
enriched	NULL
SR-BP	NULL
preparation	NULL
from	NULL
Superdex	NULL
200	NULL
HR	NULL
chromatography	NULL
in	NULL
Freund	NULL
's	NULL
complete	NULL
adjuvant	NULL
.	NULL

On	NULL
days	NULL
30	NULL
and	NULL
60	NULL
,	NULL
mice	NULL
were	NULL
boosted	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
proteins	NULL
in	NULL
incomplete	NULL
Freund	NULL
's	NULL
adjuvant	NULL
.	NULL

Sera	NULL
were	NULL
collected	NULL
on	NULL
days	NULL
38	NULL
and	NULL
68	NULL
,	NULL
diluted	NULL
to	NULL
100	NULL
pl	NULL
in	NULL
PBS	NULL
buffer	NULL
containing	NULL
0.1	NULL
%	NULL
BSA	NULL
and	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
and	NULL
then	NULL
incubated	NULL
for	NULL
16	NULL
h	NULL
at	NULL
4°C	NULL
with	NULL
100	NULL
pl	NULL
of	NULL
solution	NULL
containing	NULL
5000	NULL
dpm	NULL
of	NULL
|°HJSR-BP	NULL
.	NULL

Separation	NULL
of	NULL
free	NULL
and	NULL
bound	NULL
antibodies	NULL
was	NULL
obtained	NULL
by	NULL
addition	NULL
of	NULL
1	NULL
ml	NULL
of	NULL
20	NULL
%	NULL
polyethylene	NULL
glycol	NULL
4000	NULL
,	NULL
followed	NULL
by	NULL
a	NULL
centrifugation	NULL
at	NULL
4000	NULL
x	NULL
g.	NULL
The	NULL
pellet	NULL
containing	NULL
bound	NULL
antibodies	NULL
was	NULL
dissolved	NULL
in	NULL
1	NULL
ml	NULL
of	NULL
PBS	NULL
mixed	NULL
with	NULL
10	NULL
ml	NULL
of	NULL
scintillation	NULL
liquid	NULL
and	NULL
counted	NULL
for	NULL
radioactivity	NULL
.	NULL

For	NULL
the	NULL
production	NULL
of	NULL
monoclonal	NULL
antibodies	NULL
,	NULL
3	NULL
days	NULL
before	NULL
fusion	NULL
,	NULL
mice	NULL
were	NULL
boosted	NULL
intravenously	NULL
with	NULL
10	NULL
ug	NULL
of	NULL
proteins	NULL
.	NULL

Splenocytes	NULL
were	NULL
collected	NULL
and	NULL
fused	NULL
with	NULL
P3	NULL
X	NULL
68Ag8.653	NULL
mouse	NULL
myeloma	NULL
cells	NULL
.	NULL

Screening	NULL
for	NULL
anti-SR-BP	NULL
antibodies	NULL
was	NULL
performed	NULL
using	NULL
[	NULL
°HJSR-BP	NULL
.	NULL

Antibodies	NULL
were	NULL
produced	NULL
in	NULL
mice	NULL
and	NULL
purified	NULL
from	NULL
ascitic	NULL
fluid	NULL
by	NULL
affinity	NULL
chromatography	NULL
on	NULL
protein	NULL
A-Sepharose	NULL
.	NULL

Electrophoresis	NULL
and	NULL
Immunoblot	NULL
SDS-PAGE	NULL
was	NULL
performed	NULL
according	NULL
to	NULL
Laemmli	NULL
(	NULL
27	NULL
)	NULL
.	NULL

Proteins	NULL
were	NULL
transferred	NULL
electrophoretically	NULL
to	NULL
nitrocellulose	NULL
membrane	NULL
.	NULL

The	NULL
membrane	NULL
was	NULL
incubated	NULL
for	NULL
1	NULL
h	NULL
at	NULL
20	NULL
°C	NULL
in	NULL
5	NULL
%	NULL
nonfat	NULL
dry	NULL
milk	NULL
in	NULL
0.1	NULL
%	NULL
Tween	NULL
20	NULL
,	NULL
150	NULL
mM	NULL
NaCl	NULL
,	NULL
20	NULL
mM	NULL
Tris-HCl	NULL
,	NULL
pH	NULL
7.4	NULL
,	NULL
then	NULL
for	NULL
1	NULL
h	NULL
at	NULL
20	NULL
°C	NULL
with	NULL
monoclonal	NULL
antibody	NULL
at	NULL
0.5	NULL
ug/ml	NULL
in	NULL
the	NULL
same	NULL
buffer	NULL
.	NULL

Peroxidase-conjugated	NULL
goat	NULL
anti-mouse	NULL
antibodies	NULL
were	NULL
added	NULL
,	NULL
and	NULL
protein	NULL
detection	NULL
was	NULL
performed	NULL
with	NULL
ECL	NULL
kit	NULL
(	NULL
Amersham	NULL
)	NULL
as	NULL
described	NULL
in	NULL
the	NULL
manufacturer	NULL
's	NULL
protocol	NULL
.	NULL

Partial	NULL
Amino	NULL
Acid	NULL
Sequencing	NULL
of	NULL
SR-BP	NULL
Immunopurified	NULL
SR-BP	NULL
was	NULL
subjected	NULL
to	NULL
SDS-PAGE	NULL
.	NULL

After	NULL
gel	NULL
staining	NULL
with	NULL
Coomassie	NULL
Blue	NULL
G-250	NULL
,	NULL
the	NULL
28-kDa	NULL
band	NULL
was	NULL
cut	NULL
out	NULL
and	NULL
subjected	NULL
to	NULL
trypsin	NULL
hydrolysis	NULL
,	NULL
which	NULL
generated	NULL
six	NULL
distinct	NULL
peptides	NULL
.	NULL

Edman	NULL
's	NULL
degradation	NULL
was	NULL
performed	NULL
using	NULL
an	NULL
Applied	NULL
Biosystems	NULL
model	NULL
477A	NULL
pulse-liquid	NULL
sequenator	NULL
connected	NULL
on	NULL
line	NULL
to	NULL
an	NULL
RP-HPLC	NULL
unit	NULL
(	NULL
model	NULL
120A	NULL
,	NULL
Applied	NULL
Biosystems	NULL
)	NULL
(	NULL
28	NULL
)	NULL
.	NULL

Molecular	NULL
Cloning	NULL
of	NULL
Human	NULL
SR-BP	NULL
cDNA	NULL
Two	NULL
degenerate	NULL
oligonucleotides	NULL
were	NULL
designed	NULL
based	NULL
on	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
longer	NULL
peptide	NULL
(	NULL
these	NULL
were	NULL
derived	NULL
from	NULL
GARGT-NTTYTAYCCIGGIGARAC	NULL
(	NULL
sense	NULL
)	NULL
and	NULL
from	NULL
CATVCANGTRTTIGGIC-CCCAYTC	NULL
(	NULL
antisense	NULL
)	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

8	NULL
)	NULL
.	NULL

PCR	NULL
was	NULL
performed	NULL
using	NULL
100	NULL
ng	NULL
of	NULL
first	NULL
strand	NULL
cDNA	NULL
prepared	NULL
from	NULL
Daudi	NULL
mRNA	NULL
.	NULL

The	NULL
80-bp	NULL
PCR	NULL
product	NULL
was	NULL
further	NULL
subcloned	NULL
into	NULL
PGEM-T	NULL
vector	NULL
(	NULL
Promega	NULL
,	NULL
Madison	NULL
,	NULL
WI	NULL
)	NULL
and	NULL
sequenced	NULL
.	NULL

Two	NULL
matched	NULL
antisense	NULL
primers	NULL
(	NULL
AS1l	NULL
:	NULL
5'-GC-CCCACTCCACAGCTGTTGCCTC-3	NULL
'	NULL
;	NULL
AS2	NULL
:	NULL
5'-ACCAGGCCCGTGTAC-TACCGTCTC-3	NULL
'	NULL
)	NULL
complementary	NULL
to	NULL
the	NULL
middle	NULL
of	NULL
the	NULL
sequence	NULL
were	NULL
used	NULL
to	NULL
amplify	NULL
the	NULL
55	NULL
end	NULL
of	NULL
cDNA	NULL
with	NULL
the	NULL
RACE	NULL
system	NULL
(	NULL
Life	NULL
Technologies	NULL
,	NULL
Inc.	NULL
)	NULL
.	NULL

A	NULL
PCR	NULL
product	NULL
of	NULL
about	NULL
820	NULL
bp	NULL
was	NULL
subcloned	NULL
into	NULL
PGEM-T	NULL
and	NULL
sequenced	NULL
.	NULL

This	NULL
DNA	NULL
fragment	NULL
was	NULL
used	NULL
as	NULL
a	NULL
probe	NULL
to	NULL
screen	NULL
a	NULL
Daudi	NULL
A	NULL
UniZAP	NULL
XR	NULL
cDNA	NULL
library	NULL
.	NULL

The	NULL
longest	NULL
isolated	NULL
clone	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
27109	NULL
TaBLE	NULL
I	NULL
Purification	NULL
of	NULL
SR-BP	NULL
from	NULL
Ichikawa	NULL
T	NULL
cells	NULL
Proteins	NULL
31747A	NULL
binding	NULL
``	NULL
Purificati	NULL
teps®	NULL
-	NULL
Thcation	NULL
Steps	NULL
Recovery	NULL
Recovery	NULL
Fuzz-1533011	NULL
Kf	NULL
mg	NULL
protein	NULL
%	NULL
pmol/mg	NULL
%	NULL
SDG	NULL
560	NULL
100	NULL
8.2	NULL
100	NULL
1	NULL
DEAE	NULL
76	NULL
13.0	NULL
7.7	NULL
82	NULL
2	NULL
4	NULL
Mono	NULL
Q	NULL
16	NULL
2.8	NULL
21	NULL
19	NULL
6.6	NULL
Q	NULL
Hyper	NULL
D	NULL
1.4	NULL
0.25	NULL
153	NULL
12	NULL
48	NULL
200	NULL
HR	NULL
0.19	NULL
0.068	NULL
510	NULL
5.4	NULL
160	NULL
0.24	NULL
+	NULL
0.05	NULL
Anti-SRBP	NULL
Sepharose	NULL
``	NULL
0.018	NULL
0.0032	NULL
2925	NULL
8.0	NULL
914	NULL
0.22	NULL
+	NULL
0.04	NULL
*	NULL
Purification	NULL
steps	NULL
were	NULL
as	NULL
follows	NULL
:	NULL
SDG	NULL
,	NULL
crude	NULL
supernatant	NULL
of	NULL
membrane	NULL
solubilization	NULL
by	NULL
digitonin	NULL
;	NULL
DEAE	NULL
,	NULL
pooled	NULL
active	NULL
fractions	NULL
from	NULL
DEAE	NULL
Sepharose	NULL
column	NULL
;	NULL
Mono	NULL
Q	NULL
,	NULL
pooled	NULL
active	NULL
fractions	NULL
from	NULL
Mono	NULL
Q	NULL
column	NULL
;	NULL
Q	NULL
Hyper	NULL
D	NULL
,	NULL
pooled	NULL
active	NULL
fractions	NULL
from	NULL
Q	NULL
Hyper	NULL
D	NULL
column	NULL
;	NULL
HR	NULL
200	NULL
,	NULL
pooled	NULL
active	NULL
fractions	NULL
from	NULL
Superdex	NULL
HR	NULL
200	NULL
column	NULL
;	NULL
anti-SR-BP-Sepharose	NULL
,	NULL
pooled	NULL
active	NULL
fractions	NULL
from	NULL
the	NULL
affinity	NULL
anti-SR-BP	NULL
column	NULL
.	NULL

*	NULL
31747A	NULL
binding	NULL
was	NULL
determined	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

©	NULL
Scatchard	NULL
analysis	NULL
of	NULL
specific	NULL
[	NULL
°HIJSR	NULL
81747	NULL
binding	NULL
to	NULL
purified	NULL
fractions	NULL
;	NULL
purified	NULL
HR200	NULL
fraction	NULL
(	NULL
450	NULL
ng/ml	NULL
)	NULL
or	NULL
immunopurified	NULL
fraction	NULL
(	NULL
144	NULL
ng/ml	NULL
)	NULL
were	NULL
incubated	NULL
for	NULL
2	NULL
h	NULL
at	NULL
20	NULL
°C	NULL
with	NULL
[	NULL
°HJSR	NULL
31747	NULL
(	NULL
0.08-8.0	NULL
nM	NULL
)	NULL
.	NULL

Nonspecific	NULL
binding	NULL
was	NULL
determined	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
1	NULL
uM	NULL
SR	NULL
31747A	NULL
.	NULL

@	NULL
Direct	NULL
purification	NULL
from	NULL
DEAE	NULL
fraction	NULL
using	NULL
anti-SR-BP	NULL
antibody	NULL
.	NULL

was	NULL
fully	NULL
sequenced	NULL
,	NULL
and	NULL
sequence	NULL
analyses	NULL
were	NULL
performed	NULL
with	NULL
Blast	NULL
(	NULL
29	NULL
)	NULL
.	NULL

Amino	NULL
acid	NULL
sequence	NULL
alignment	NULL
was	NULL
produced	NULL
by	NULL
the	NULL
clustal	NULL
W	NULL
program	NULL
.	NULL

Expression	NULL
of	NULL
SR-BP	NULL
cDNA	NULL
in	NULL
S.	NULL
cerevisiae	NULL
The	NULL
open	NULL
reading	NULL
frame	NULL
of	NULL
SR-BP	NULL
was	NULL
cloned	NULL
by	NULL
PCR	NULL
amplification	NULL
using	NULL
two	NULL
oligonucleotides	NULL
,	NULL
A	NULL
and	NULL
B	NULL
.	NULL

The	NULL
oligonucleotide	NULL
sequence	NULL
of	NULL
A	NULL
(	NULL
forward	NULL
,	NULL
BamHI	NULL
,	NULL
Salil	NULL
)	NULL
was	NULL
as	NULL
follows	NULL
:	NULL
ATCAGGATCCGTCGACAA-CATGCAATGGGCTGTTGGTAGACGGTGGGCGTGGGCC	NULL
)	NULL
and	NULL
corresponded	NULL
to	NULL
the	NULL
first	NULL
12	NULL
codons	NULL
of	NULL
SR-BP	NULL
with	NULL
some	NULL
modifications	NULL
at	NULL
the	NULL
DNA	NULL
level	NULL
to	NULL
improve	NULL
mRNA	NULL
translation	NULL
.	NULL

The	NULL
oligonucleotide	NULL
sequence	NULL
of	NULL
B	NULL
(	NULL
reverse	NULL
,	NULL
BamHI	NULL
,	NULL
XbaI	NULL
)	NULL
corresponded	NULL
to	NULL
positions	NULL
+662	NULL
to	NULL
+684	NULL
(	NULL
relative	NULL
to	NULL
the	NULL
first	NULL
base	NULL
of	NULL
the	NULL
initiation	NULL
codon	NULL
)	NULL
.	NULL

The	NULL
amplified	NULL
DNA	NULL
fragment	NULL
was	NULL
cloned	NULL
between	NULL
the	NULL
Sail	NULL
and	NULL
BamHI	NULL
sites	NULL
of	NULL
the	NULL
pEMR1023	NULL
polylinker	NULL
(	NULL
28	NULL
)	NULL
to	NULL
yield	NULL
pEMR1499	NULL
,	NULL
a	NULL
multicopy	NULL
E.	NULL
coli-S.	NULL
cerevisiae	NULL
shuttle	NULL
vector	NULL
containing	NULL
URA3	NULL
as	NULL
the	NULL
selective	NULL
marker	NULL
.	NULL

The	NULL
SR-BP	NULL
open	NULL
reading	NULL
frame	NULL
was	NULL
expressed	NULL
under	NULL
the	NULL
control	NULL
of	NULL
the	NULL
PGK	NULL
promoter	NULL
.	NULL

Northern	NULL
Blot	NULL
Analysis	NULL
The	NULL
expression	NULL
of	NULL
SR-BP	NULL
mRNA	NULL
in	NULL
human	NULL
tissues	NULL
was	NULL
examined	NULL
by	NULL
Northern	NULL
blot	NULL
analysis	NULL
using	NULL
membranes	NULL
purchased	NULL
from	NULL
CLONTECH	NULL
(	NULL
Palo	NULL
Alto	NULL
,	NULL
CA	NULL
)	NULL
.	NULL

Hybridization	NULL
was	NULL
carried	NULL
out	NULL
in	NULL
Church	NULL
buffer	NULL
(	NULL
30	NULL
)	NULL
with	NULL
a	NULL
*°P-labeled	NULL
300-bp	NULL
probe	NULL
specific	NULL
for	NULL
SR-BP	NULL
cDNA	NULL
.	NULL

Autoradiog-	NULL
raphy	NULL
was	NULL
performed	NULL
overnight	NULL
with	NULL
an	NULL
intensifying	NULL
screen	NULL
.	NULL

Analysis	NULL
of	NULL
Subcellular	NULL
Localization	NULL
of	NULL
SR-BP	NULL
by	NULL
Confocal	NULL
Microscopy	NULL
Cells	NULL
were	NULL
fixed	NULL
overnight	NULL
with	NULL
1	NULL
%	NULL
formaldehyde	NULL
at	NULL
4°C	NULL
,	NULL
washed	NULL
once	NULL
in	NULL
PBS	NULL
,	NULL
and	NULL
permeabilized	NULL
for	NULL
10	NULL
min	NULL
with	NULL
a	NULL
solution	NULL
of	NULL
0.1	NULL
%	NULL
saponin	NULL
in	NULL
PBS	NULL
containing	NULL
1	NULL
%	NULL
BSA	NULL
.	NULL

Biotinylated	NULL
conjugated	NULL
anti-SR-BP	NULL
mAb	NULL
,	NULL
and	NULL
anti-mitochondria	NULL
M117	NULL
or	NULL
anti-nuclear	NULL
membrane	NULL
AE-5	NULL
mAbs	NULL
(	NULL
Leinco	NULL
Technologies	NULL
Inc.	NULL
,	NULL
St.	NULL
Louis	NULL
,	NULL
MO	NULL
)	NULL
were	NULL
simultaneously	NULL
incubated	NULL
with	NULL
cells	NULL
in	NULL
the	NULL
0.1	NULL
%	NULL
saponin	NULL
,	NULL
1	NULL
%	NULL
BSA	NULL
solution	NULL
for	NULL
30	NULL
min	NULL
at	NULL
room	NULL
temperature	NULL
.	NULL

After	NULL
two	NULL
washes	NULL
,	NULL
cells	NULL
were	NULL
simultaneously	NULL
incubated	NULL
for	NULL
30	NULL
min	NULL
with	NULL
fluorescein	NULL
isothiocyanate-conju-gated	NULL
goat	NULL
anti-mouse	NULL
IgG1	NULL
Abs	NULL
(	NULL
Southern	NULL
Biotechnology	NULL
Inc.	NULL
,	NULL
Birming-ham	NULL
,	NULL
AL	NULL
)	NULL
to	NULL
stain	NULL
M117	NULL
or	NULL
AE-5	NULL
mAbs	NULL
,	NULL
and	NULL
with	NULL
Cy5-conjugated	NULL
streptavidin	NULL
(	NULL
from	NULL
Jackson	NULL
Immunoresearch	NULL
,	NULL
West	NULL
Grove	NULL
,	NULL
PA	NULL
)	NULL
to	NULL
stain	NULL
biotinylated	NULL
conjugated	NULL
anti-SR-BP	NULL
mAb	NULL
.	NULL

Cell	NULL
pellets	NULL
were	NULL
resuspended	NULL
in	NULL
20	NULL
pl	NULL
of	NULL
glycerol	NULL
containing	NULL
the	NULL
anti-bleaching	NULL
reagent	NULL
DABCO	NULL
at	NULL
50	NULL
mg/ml	NULL
.	NULL

A	NULL
laser-scanning	NULL
confocal	NULL
microscope	NULL
(	NULL
LSM410	NULL
,	NULL
Zeiss	NULL
,	NULL
Oberkochen	NULL
,	NULL
Germany	NULL
)	NULL
equipped	NULL
with	NULL
a	NULL
planapo	NULL
oil	NULL
(	NULL
X	NULL
63	NULL
)	NULL
immersion	NULL
lens	NULL
(	NULL
numerical	NULL
aperture	NULL
=	NULL
1.4	NULL
)	NULL
was	NULL
used	NULL
to	NULL
analyze	NULL
the	NULL
three-dimen-sional	NULL
distribution	NULL
of	NULL
SR-BP	NULL
as	NULL
described	NULL
previously	NULL
(	NULL
31	NULL
)	NULL
.	NULL

In	NULL
Vitro	NULL
Lymphocyte	NULL
Proliferation	NULL
Mouse	NULL
splenocytes	NULL
were	NULL
cultured	NULL
in	NULL
96-well	NULL
flat-bottomed	NULL
plates	NULL
in	NULL
quadruplicate	NULL
at	NULL
4	NULL
X	NULL
10°	NULL
cells/well	NULL
with	NULL
1	NULL
pg/ml	NULL
staphylococcal	NULL
enterotoxin	NULL
B	NULL
.	NULL

Cells	NULL
were	NULL
cultured	NULL
in	NULL
complete	NULL
medium	NULL
for	NULL
4	NULL
days	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
various	NULL
concentrations	NULL
of	NULL
SR	NULL
81747	NULL
or	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
,	NULL
then	NULL
pulsed	NULL
with	NULL
1	NULL
pCi/well	NULL
[	NULL
*HIthymidine	NULL
(	NULL
Amersham	NULL
,	NULL
les	NULL
Ulis	NULL
,	NULL
France	NULL
)	NULL
,	NULL
and	NULL
harvested	NULL
4	NULL
h	NULL
later	NULL
on	NULL
glass	NULL
fiber	NULL
papers	NULL
using	NULL
a	NULL
Skatron	NULL
harvester	NULL
system	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

Incorporated	NULL
radioactivity	NULL
was	NULL
measured	NULL
by	NULL
using	NULL
a	NULL
Betaplate	NULL
liquid	NULL
scintillation	NULL
spectrometer	NULL
(	NULL
Pharmacia	NULL
)	NULL
.	NULL

RESULTS	NULL
Purification	NULL
of	NULL
Human	NULL
SR-BP-Results	NULL
of	NULL
SR-BP	NULL
purifica-	NULL
tion	NULL
from	NULL
human	NULL
T	NULL
leukemia	NULL
Ichikawa	NULL
cells	NULL
are	NULL
summarized	NULL
in	NULL
Table	NULL
I	NULL
.	NULL

From	NULL
the	NULL
solubilized	NULL
membrane	NULL
preparation	NULL
,	NULL
the	NULL
binding	NULL
activity	NULL
was	NULL
eluted	NULL
as	NULL
a	NULL
single	NULL
peak	NULL
with	NULL
DEAE	NULL
anion	NULL
exchange	NULL
chromatography	NULL
.	NULL

A	NULL
straightforward	NULL
enrichment	NULL
of	NULL
SR-BP	NULL
was	NULL
obtained	NULL
using	NULL
Mono	NULL
Q	NULL
gel	NULL
followed	NULL
by	NULL
Q	NULL
Hyper	NULL
D	NULL
gel	NULL
.	NULL

The	NULL
apparent	NULL
size	NULL
of	NULL
SR-BP	NULL
determined	NULL
by	NULL
gel	NULL
filtration	NULL
gave	NULL
a	NULL
value	NULL
of	NULL
approximately	NULL
100	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

1	NULL
)	NULL
,	NULL
whereas	NULL
electrophoresis	NULL
revealed	NULL
several	NULL
bands	NULL
between	NULL
80	NULL
and	NULL
100	NULL
kDa	NULL
and	NULL
a	NULL
band	NULL
close	NULL
to	NULL
30	NULL
kDa	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
,	NULL
lane	NULL
5	NULL
)	NULL
.	NULL

At	NULL
this	NULL
stage	NULL
,	NULL
the	NULL
enriched	NULL
SRBP	NULL
preparation	NULL
was	NULL
used	NULL
to	NULL
immunize	NULL
animals	NULL
to	NULL
generate	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
against	NULL
SR-BP	NULL
for	NULL
further	NULL
purification	NULL
.	NULL

We	NULL
developed	NULL
a	NULL
screening	NULL
test	NULL
for	NULL
antibody	NULL
detection	NULL
,	NULL
taking	NULL
advantage	NULL
of	NULL
the	NULL
fact	NULL
that	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
PHJSR	NULL
31747A	NULL
to	NULL
partially	NULL
purified	NULL
SR-BP	NULL
was	NULL
not	NULL
dissociated	NULL
upon	NULL
gel	NULL
filtration	NULL
chromatography	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

1	NULL
,	NULL
Q	NULL
Hyper	NULL
D	NULL
fraction	NULL
incubated	NULL
with	NULL
[	NULL
PHJSR	NULL
31747	NULL
gave	NULL
a	NULL
single	NULL
radioactive	NULL
peak	NULL
associated	NULL
with	NULL
eluted	NULL
proteins	NULL
.	NULL

We	NULL
used	NULL
this	NULL
property	NULL
to	NULL
prepare	NULL
a	NULL
[	NULL
°PH	NULL
]	NULL
JSR	NULL
31747A/SR-BP	NULL
complex	NULL
(	NULL
tritiated	NULL
antigen	NULL
)	NULL
for	NULL
radio-immunoassay	NULL
to	NULL
detect	NULL
antibody	NULL
specific	NULL
to	NULL
SR-BP	NULL
.	NULL

The	NULL
hybri-doma	NULL
30G10	NULL
producing	NULL
the	NULL
antibody	NULL
with	NULL
the	NULL
highest	NULL
affinity	NULL
was	NULL
selected	NULL
;	NULL
antibodies	NULL
were	NULL
produced	NULL
in	NULL
mice	NULL
,	NULL
purified	NULL
,	NULL
and	NULL
linked	NULL
to	NULL
CNBr-Sepharose	NULL
.	NULL

The	NULL
subsequent	NULL
immunopurifica-tion	NULL
step	NULL
drastically	NULL
improved	NULL
the	NULL
purity	NULL
of	NULL
SR-BP	NULL
(	NULL
Table	NULL
I	NULL
)	NULL
since	NULL
only	NULL
a	NULL
single	NULL
band	NULL
of	NULL
28	NULL
kDa	NULL
could	NULL
be	NULL
detected	NULL
by	NULL
silver	NULL
staining	NULL
and	NULL
immunobloting	NULL
(	NULL
Fig	NULL
.	NULL

2	NULL
)	NULL
.	NULL

In	NULL
the	NULL
purified	NULL
preparation	NULL
,	NULL
the	NULL
SR	NULL
31747	NULL
binding	NULL
activity	NULL
was	NULL
enriched	NULL
914-fold	NULL
over	NULL
the	NULL
crude	NULL
digitonin	NULL
extract	NULL
.	NULL

This	NULL
preparation	NULL
was	NULL
used	NULL
for	NULL
partial	NULL
amino	NULL
acid	NULL
sequencing	NULL
.	NULL

SR-BP	NULL
eDNA	NULL
Cloning-To	NULL
isolate	NULL
the	NULL
human	NULL
SR-BP-encod-ing	NULL
cDNA	NULL
,	NULL
we	NULL
used	NULL
the	NULL
trypsic	NULL
peptides	NULL
obtained	NULL
from	NULL
the	NULL
purified	NULL
human	NULL
SR-BP	NULL
protein	NULL
.	NULL

Based	NULL
on	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
longest	NULL
peptide	NULL
,	NULL
reverse	NULL
transcriptase-PCR	NULL
and	NULL
then	NULL
5	NULL
RACE	NULL
experiments	NULL
led	NULL
us	NULL
to	NULL
clone	NULL
a	NULL
320-bp	NULL
fragment	NULL
.	NULL

This	NULL
fragment	NULL
was	NULL
then	NULL
used	NULL
to	NULL
screen	NULL
an	NULL
oligo	NULL
(	NULL
dT	NULL
)	NULL
-primed	NULL
Daudi	NULL
cDNA	NULL
library	NULL
in	NULL
A	NULL
UniZAP	NULL
phage	NULL
.	NULL

The	NULL
cDNA	NULL
and	NULL
deduced	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
the	NULL
largest	NULL
clone	NULL
are	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

3	NULL
.	NULL

This	NULL
cDNA	NULL
contained	NULL
a	NULL
669-bp	NULL
open	NULL
reading	NULL
frame	NULL
with	NULL
untranslated	NULL
regions	NULL
of	NULL
74	NULL
bp	NULL
at	NULL
the	NULL
5'-end	NULL
,	NULL
906	NULL
bp	NULL
at	NULL
the	NULL
3'-end	NULL
,	NULL
and	NULL
a	NULL
consensus	NULL
polyadenylation	NULL
signal	NULL
(	NULL
AATAAA	NULL
)	NULL
16	NULL
bp	NULL
upstream	NULL
from	NULL
the	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
tail	NULL
.	NULL

Translation	NULL
of	NULL
this	NULL
open	NULL
reading	NULL
frame	NULL
yielded	NULL
a	NULL
223-amino	NULL
acid	NULL
protein	NULL
with	NULL
a	NULL
calculated	NULL
molecular	NULL
mass	NULL
of	NULL
24.8	NULL
kDa	NULL
.	NULL

Comparisons	NULL
to	NULL
the	NULL
GenBank	NULL
data	NULL
base	NULL
revealed	NULL
that	NULL
human	NULL
SR-BP	NULL
displayed	NULL
93	NULL
%	NULL
amino	NULL
acid	NULL
sequence	NULL
identity	NULL
with	NULL
the	NULL
predicted	NULL
amino	NULL
acid	NULL
sequence	NULL
of	NULL
a	NULL
guinea	NULL
pig	NULL
protein	NULL
called	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
27110	NULL
1-	NULL
20	NULL
8	NULL
4	NULL
5	NULL
Q/	NULL
¢	NULL
¢	NULL
\|/	NULL
Q/	NULL
-70	NULL
(	NULL
16	NULL
0,04	NULL
-	NULL
7	NULL
baa	NULL
12	NULL
I	NULL
0,03	NULL
-	NULL
i	NULL
-	NULL
102	NULL
&	NULL
E	NULL
-	NULL
s	NULL
2	NULL
s	NULL
0,02	NULL
-	NULL
a	NULL
S	NULL
-o	NULL
0,01	NULL
-	NULL
|-	NULL
2	NULL
0,00	NULL
-	NULL
-	NULL
o	NULL
min	NULL
Fic	NULL
.	NULL

1	NULL
.	NULL

Superdex	NULL
HR	NULL
200	NULL
chromatography	NULL
.	NULL

The	NULL
active	NULL
fractions	NULL
from	NULL
Q	NULL
Hyper	NULL
D	NULL
were	NULL
pooled	NULL
,	NULL
concentrated	NULL
,	NULL
and	NULL
passed	NULL
through	NULL
a	NULL
Superdex	NULL
HR200	NULL
column	NULL
,	NULL
either	NULL
directly	NULL
,	NULL
the	NULL
fractions	NULL
being	NULL
assayed	NULL
for	NULL
PHJISR	NULL
317474	NULL
binding	NULL
(	NULL
0	NULL
)	NULL
,	NULL
or	NULL
after	NULL
a	NULL
2-h	NULL
preincubation	NULL
with	NULL
20	NULL
nM	NULL
PHJISR	NULL
31747A	NULL
,	NULL
after	NULL
which	NULL
the	NULL
radioactivity	NULL
was	NULL
measured	NULL
in	NULL
each	NULL
fraction	NULL
(	NULL
V	NULL
)	NULL
.	NULL

The	NULL
arrows	NULL
indicate	NULL
the	NULL
elution	NULL
positions	NULL
of	NULL
molecular	NULL
size	NULL
markers	NULL
:	NULL
I	NULL
,	NULL
ferritin	NULL
(	NULL
440	NULL
kDa	NULL
)	NULL
;	NULL
2	NULL
,	NULL
catalase	NULL
(	NULL
282	NULL
kDa	NULL
)	NULL
;	NULL
3	NULL
,	NULL
aldolase	NULL
(	NULL
158	NULL
kDa	NULL
)	NULL
;	NULL
4	NULL
,	NULL
bovine	NULL
serum	NULL
albumin	NULL
(	NULL
67	NULL
kDa	NULL
)	NULL
;	NULL
5	NULL
,	NULL
ovalbumin	NULL
(	NULL
43	NULL
kDa	NULL
)	NULL
.	NULL

Mr	NULL
x	NULL
108	NULL
1	NULL
2	NULL
3	NULL
4	NULL
5	NULL
6	NULL
7	NULL
8	NULL
202	NULL
-	NULL
q	NULL
137	NULL
79	NULL
-|	NULL
%	NULL
g	NULL
-	NULL
s	NULL
42.3	NULL
-	NULL
Q	NULL
#	NULL
~-	NULL
<	NULL
n	NULL
31.67	NULL
Q	NULL
.	NULL

18	NULL
4	NULL
Fic	NULL
.	NULL

2	NULL
.	NULL

SDS-PAGE	NULL
during	NULL
SR-BP	NULL
purification	NULL
.	NULL

Lane	NULL
1	NULL
,	NULL
molecular	NULL
size	NULL
markers	NULL
;	NULL
lane	NULL
2	NULL
,	NULL
digitonin-solubilized	NULL
membrane	NULL
(	NULL
40	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
3	NULL
,	NULL
DEAE-Sepharose	NULL
fraction	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
4	NULL
,	NULL
Mono	NULL
Q-Sepharose	NULL
fraction	NULL
(	NULL
20	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
5	NULL
,	NULL
Q	NULL
Hyper	NULL
D	NULL
fraction	NULL
(	NULL
6	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
6	NULL
,	NULL
HR	NULL
200	NULL
fraction	NULL
(	NULL
3	NULL
ug	NULL
)	NULL
;	NULL
lane	NULL
7	NULL
,	NULL
affinity	NULL
fraction	NULL
(	NULL
1	NULL
ug	NULL
)	NULL
.	NULL

The	NULL
gel	NULL
(	NULL
12	NULL
%	NULL
acrylamide	NULL
)	NULL
was	NULL
stained	NULL
with	NULL
Coomassie	NULL
Blue	NULL
;	NULL
lane	NULL
8	NULL
,	NULL
immunoblot	NULL
of	NULL
the	NULL
immunopurified	NULL
fraction	NULL
.	NULL

sigma	NULL
1	NULL
receptor	NULL
(	NULL
32	NULL
)	NULL
and	NULL
was	NULL
further	NULL
found	NULL
identical	NULL
to	NULL
the	NULL
recently	NULL
published	NULL
human	NULL
sigma	NULL
1	NULL
receptor	NULL
(	NULL
33	NULL
)	NULL
.	NULL

In	NULL
addition	NULL
,	NULL
a	NULL
significant	NULL
homology	NULL
(	NULL
29.9	NULL
%	NULL
amino	NULL
acid	NULL
sequence	NULL
identity	NULL
)	NULL
was	NULL
found	NULL
with	NULL
the	NULL
product	NULL
of	NULL
the	NULL
gene	NULL
ERG2	NULL
,	NULL
a	NULL
fungal	NULL
gene	NULL
encoding	NULL
a	NULL
sterol	NULL
isomerase	NULL
(	NULL
34	NULL
)	NULL
.	NULL

It	NULL
is	NULL
noteworthy	NULL
that	NULL
we	NULL
have	NULL
already	NULL
shown	NULL
that	NULL
ERGZP	NULL
is	NULL
the	NULL
molecular	NULL
target	NULL
of	NULL
SR	NULL
31747A	NULL
in	NULL
yeast	NULL
(	NULL
23	NULL
)	NULL
.	NULL

The	NULL
three	NULL
proteins	NULL
shared	NULL
the	NULL
same	NULL
hydropathy	NULL
plot	NULL
,	NULL
including	NULL
a	NULL
highly	NULL
hydrophobic	NULL
domain	NULL
located	NULL
at	NULL
the	NULL
N	NULL
terminus	NULL
,	NULL
with	NULL
a	NULL
second	NULL
stretch	NULL
of	NULL
hydrophobic	NULL
amino	NULL
acids	NULL
located	NULL
in	NULL
the	NULL
middle	NULL
of	NULL
these	NULL
proteins	NULL
.	NULL

Multiple	NULL
alignments	NULL
showed	NULL
that	NULL
this	NULL
domain	NULL
is	NULL
highly	NULL
conserved	NULL
among	NULL
human	NULL
SR-BP	NULL
,	NULL
guinea	NULL
pig	NULL
sigma	NULL
1	NULL
receptor	NULL
,	NULL
and	NULL
the	NULL
ERG2	NULL
gene	NULL
product	NULL
from	NULL
yeast	NULL
S.	NULL
cerevisiae	NULL
as	NULL
well	NULL
as	NULL
from	NULL
other	NULL
fungi	NULL
(	NULL
Magnaportae	NULL
grisea	NULL
,	NULL
Ustilago	NULL
maydis	NULL
,	NULL
Neurospora	NULL
crassa	NULL
)	NULL
(	NULL
Fig	NULL
.	NULL

4	NULL
)	NULL
.	NULL

SR-BP	NULL
Expression-We	NULL
next	NULL
investigated	NULL
SR-BP	NULL
functions	NULL
by	NULL
first	NULL
transfecting	NULL
SR-BP	NULL
cDNA	NULL
in	NULL
a	NULL
different	NULL
host	NULL
cell	NULL
.	NULL

We	NULL
used	NULL
a	NULL
ERG2	NULL
gene	NULL
disruptant	NULL
strain	NULL
of	NULL
S.	NULL
cerevisiae	NULL
(	NULL
EMYA4T	NULL
)	NULL
,	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
1	NULL
CPeCeAGeCeoTeaGCecaaaGCCTcaceeccececrecerCercAccTececceTrecca	NULL
61	NULL
.	NULL

Mo	NULL
Q	NULL
w	NULL
A	NULL
V	NULL
G	NULL
R	NULL
R	NULL
W	NULL
A	NULL
W	NULL
A	NULL
A	NULL
L	NULL
L	NULL
15	NULL
121	NULL
‘	NULL
I	NULL
‘	NULL
GGC'TCTCGCAGCGGTGCTf	NULL
‘	NULL
ACCCAGGTCGTC	NULL
”	NULL
GGCTCTCGC	NULL
TGGGTACGCAGAGCTTCG	NULL
v	NULL
A	NULL
T	NULL
Q	NULL
v	NULL
v	NULL
w	NULL
Lp	NULL
w	NULL
L	NULL
§	NULL
T	NULL
q	NULL
F	NULL
35	NULL
181	NULL
TCTTCCAGCGCGAAGAGATAGCGCAGTTGGCGCGGC	NULL
AGTACGC	NULL
”	NULL
GGG	NULL
``	NULL
TGGACCACGAGC	NULL
R	NULL
Q	NULL
Y	NULL
A	NULL
@	NULL
L	NULL
D	NULL
S	NULL
E	NULL
56	NULL
241	NULL
TGGCCTTCTCTCGTCTGATLGTGGAGCTGCGGCGGCTGCACC	NULL
CAGGC	NULL
VACGTGC	NULL
TGCCCG	NULL
A	NULL
EOS	NULL
R	NULL
L	NULL
Y	NULL
F	NULL
RoR	NULL
L	NULL
H	NULL
P	NULL
75	NULL
301	NULL
ACGAGCAGC	NULL
‘	NULL
I	NULL
‘	NULL
GCAG	NULL
‘	NULL
I	NULL
‘	NULL
GGGTGTTCCTCAA	NULL
’	NULL
ICCCCC	NULL
’	NULL
I	NULL
‘	NULL
GGCTCGATGGGCQCCP	NULL
‘	NULL
I	NULL
‘	NULL
GTGCCTTC	NULL
E	NULL
E	NULL
0	NULL
Mo	NULL
G	NULL
A	NULL
M	NULL
C	NULL
95	NULL
361	NULL
TC	NULL
‘	NULL
C	NULL
‘	NULL
ACCCCTCGCTGTCCGAuTATGTGCTGCTCWTCGGCACCGCCTTGoGCTCCCGCGGCC	NULL
§	NULL
A	NULL
$	NULL
L	NULL
§	NULL
E	NULL
¥	NULL
V	NULL
L	NULL
L	NULL
F	NULL
G	NULL
T	NULL
A	NULL
L	NULL
G	NULL
S	NULL
R	NULL
G	NULL
H	NULL
116	NULL
421	NULL
AC	NULL
TC	NULL
GC	NULL
GGCGCTACTGGGCTGAGATCTCGGATAC	NULL
CATCATCTCTGGCACCTTCCACCAGT	NULL
I	NULL
1	NULL
Q	NULL
W	NULL
136	NULL
481	NULL
Gor	NULL
AGACAGGGCACCACCAAAAGTGAGGTCTTC	NULL
”	NULL
ACCCAGC	NULL
GCAGACGSTACTACACGCGC	NULL
ROB	NULL
G	NULL
T	NULL
T	NULL
K	NULL
F	NULL
Y	NULL
P	NULL
G	NULL
B	NULL
TO	NULL
V	NULL
V	NULL
H	NULL
G	NULL
>	NULL
i156	NULL
541	NULL
CTFP	NULL
’	NULL
TCACCCAACAPC	NULL
‘	NULL
TF	NULL
‘	NULL
T	NULL
‘	NULL
``	NULL
CACTC	NULL
‘	NULL
PCPPCF	NULL
‘	NULL
AAAC	NULL
‘	NULL
AC	NULL
‘	NULL
ATCFATCCTGnACTACGGCCGGG	NULL
G	NULL
B	NULL
A	NULL
T	NULL
A	NULL
VB	NULL
©	NULL
P	NULL
N	NULL
T	NULL
Y	NULL
MOV	NULL
0G	NULL
R	NULL
G	NULL
-	NULL
176	NULL
601	NULL
.	NULL

PLLLATLLACCCTGLJCCTTCGCGCTGGCCGACACTGTCTTCAGCP	NULL
CCCAGGACT	NULL
v	NULL
I	NULL
P	NULL
§	NULL
T	NULL
L	NULL
F	NULL
s	NULL
T	NULL
Q	NULL
n	NULL
r	NULL
196	NULL
661	NULL
TCCTCACCCTC'ITCTATACTCTTCGLTCCTATGCTCGGGCCCTCCGG	NULL
``	NULL
TTGAGCTCACCA	NULL
A	NULL
R	NULL
G	NULL
L	NULL
R	NULL
L	NULL
E	NULL
L	NULL
T	NULL
T	NULL
216	NULL
721	NULL
CCTACCTCTT	NULL
‘	NULL
TGCC	NULL
‘	NULL
CAFFAC	NULL
‘	NULL
CC	NULL
’	NULL
T	NULL
‘	NULL
T	NULL
‘	NULL
C	NULL
ACCAGCCAGGCCTGAAGGAACACCTGCGGATCCAC	NULL
¥	NULL
L	NULL
F	NULL
G	NULL
Q	NULL
D	NULL
P	NULL
223	NULL
781	NULL
AGGAGCGGGCAGCCCGCACATATCCACTTGCTGGAGCCCATGTTTACAGACAGGGACATA	NULL
841	NULL
.	NULL

CACCATGCAGATCCTGAGTTCCTGCTGTATGAGCAGGCATATCCATGCTTATGTATCCAA	NULL
901	NULL
ACACAGAGACCCATGGCAACAARTGAGACACATATAGATACTGAGACCTGTETGTACAGT	NULL
961	NULL
-	NULL
AGGACCATGCACTCACACCCATCTGGAGAGCCAGCCCCCECTATACCAACCCAGCCACITT	NULL
1021	NULL
GTGTTCAGACACACACATCACAGCCTTGACTCACTAACTGACGCCTTTCCATAGCTCCACA	NULL
1081	NULL
-	NULL
GCTTCCCACCTCCTCCCCACCARACCGGGGTTCTAGAGTTAAGGATGSGGGAGCGTATTA	NULL
1141	NULL
TACTGCCTCAGTCTGACTCCTCAACCCAGCAGCAATTTCACGGGATCAGCCCCAACAGCA	NULL
1201	NULL
GCTeceTPTTecaG	NULL
@	NULL
CecCCrTcaccTrecacctaTeaTeeccreccecrrcrccccrere	NULL
1261	NULL
CTCACCATATGCCTTATCCCCATTCTACTCCCCTGCTATECAAGTGCCCCTGTEGGCTTGT	NULL
1321	NULL
-	NULL
CCCCAACCCCCTCAGCAACAAAGCTCAGCTGGCCAACGACAGTAATTTGAAGAATGCTTG	NULL
1381	NULL
AAGTCAGCGTCTTCCATTCCACAAAGACCCCCATTCTTCCTTTGGGGSTATGATGTGGAA	NULL
1441	NULL
-	NULL
GCTGGTTTCAGCCCAGGACCCACCACTGAGGAGAGGATCTAGACAGGTGGGCCTAATTCC	NULL
1501	NULL
-	NULL
AAGGGCCCCTTCCTGGCCTGGAGAAGGCCTTTTACACACACACAACACATACACACACAC	NULL
1561	NULL
ACACACACATATCACAGTTTTCACACAGCCCCTGCTGCATTCTCTETCCATCTGTCTETP	NULL
1621	NULL
TCTATTAATAAAGATTTGTTGATCTGTTCCAAAAAAAAARAAAAAAAAAAAA	NULL
Fic	NULL
.	NULL

3	NULL
.	NULL

Sequence	NULL
of	NULL
human	NULL
SR-BP	NULL
cDNA	NULL
and	NULL
its	NULL
encoded	NULL
protein	NULL
.	NULL

The	NULL
deduced	NULL
protein	NULL
sequence	NULL
of	NULL
human	NULL
SR-BP	NULL
is	NULL
shown	NULL
below	NULL
the	NULL
cDNA	NULL
sequence	NULL
.	NULL

The	NULL
numbers	NULL
on	NULL
the	NULL
left	NULL
refer	NULL
to	NULL
the	NULL
nucleotide	NULL
sequence	NULL
;	NULL
numbers	NULL
on	NULL
the	NULL
right	NULL
refer	NULL
to	NULL
the	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

The	NULL
underlined	NULL
sequences	NULL
indicate	NULL
the	NULL
tryptic	NULL
peptides	NULL
.	NULL

The	NULL
ATG	NULL
of	NULL
the	NULL
open	NULL
reading	NULL
frame	NULL
and	NULL
the	NULL
consensus	NULL
polyadenylation	NULL
signal	NULL
(	NULL
AATAAA	NULL
)	NULL
are	NULL
in	NULL
bold	NULL
letters	NULL
.	NULL

The	NULL
asterisk	NULL
denotes	NULL
the	NULL
termination	NULL
codon	NULL
.	NULL

as	NULL
host	NULL
to	NULL
express	NULL
SR-BP	NULL
.	NULL

Untransformed	NULL
EMY47	NULL
cells	NULL
did	NULL
not	NULL
detectably	NULL
display	NULL
any	NULL
SR-BP	NULL
binding	NULL
sites	NULL
.	NULL

In	NULL
contrast	NULL
,	NULL
SRBP	NULL
-expressing	NULL
cells	NULL
exhibited	NULL
SR	NULL
31747A	NULL
binding	NULL
sites	NULL
at	NULL
a	NULL
high	NULL
level	NULL
.	NULL

Flow	NULL
cytometry	NULL
analysis	NULL
showed	NULL
a	NULL
marked	NULL
labeling	NULL
in	NULL
SR-BP	NULL
-expressing	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
results	NULL
confirmed	NULL
that	NULL
the	NULL
cDNA	NULL
sequence	NULL
encoded	NULL
the	NULL
SR-BP	NULL
protein	NULL
.	NULL

Analysis	NULL
of	NULL
the	NULL
SR-BP	NULL
transcript	NULL
expression	NULL
by	NULL
Northern	NULL
blotting	NULL
identified	NULL
a	NULL
major	NULL
band	NULL
of	NULL
2	NULL
kilobases	NULL
(	NULL
Fig	NULL
.	NULL

5A	NULL
)	NULL
.	NULL

The	NULL
human	NULL
tissues	NULL
that	NULL
contained	NULL
the	NULL
highest	NULL
amount	NULL
of	NULL
human	NULL
SR-BP	NULL
mRNA	NULL
were	NULL
liver	NULL
along	NULL
with	NULL
colon	NULL
,	NULL
prostate	NULL
,	NULL
placenta	NULL
,	NULL
small	NULL
intestine	NULL
,	NULL
heart	NULL
,	NULL
and	NULL
pancreas	NULL
.	NULL

SR-BP	NULL
mRNA	NULL
is	NULL
also	NULL
present	NULL
at	NULL
a	NULL
slightly	NULL
lower	NULL
level	NULL
in	NULL
spleen	NULL
,	NULL
lung	NULL
,	NULL
thymus	NULL
,	NULL
ovary	NULL
,	NULL
peripheral	NULL
blood	NULL
leukocytes	NULL
,	NULL
and	NULL
brain	NULL
.	NULL

These	NULL
observations	NULL
were	NULL
confirmed	NULL
in	NULL
the	NULL
human	NULL
Master	NULL
Blot	NULL
(	NULL
Fig	NULL
.	NULL

5B	NULL
)	NULL
.	NULL

Subcellular	NULL
distribution	NULL
of	NULL
SR-BP	NULL
was	NULL
examined	NULL
in	NULL
the	NULL
human	NULL
promonocytic	NULL
cell	NULL
line	NULL
THP1	NULL
by	NULL
immunological	NULL
analysis	NULL
using	NULL
confocal	NULL
microscopy	NULL
.	NULL

Cells	NULL
were	NULL
simultaneously	NULL
labeled	NULL
with	NULL
anti-SR-BP	NULL
mAb	NULL
and	NULL
mAbs	NULL
specific	NULL
for	NULL
different	NULL
subcellular	NULL
organelles	NULL
.	NULL

We	NULL
clearly	NULL
observed	NULL
SR-BP	NULL
localized	NULL
in	NULL
association	NULL
with	NULL
the	NULL
nuclear	NULL
envelope	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
.	NULL

This	NULL
localization	NULL
was	NULL
also	NULL
observed	NULL
on	NULL
a	NULL
variety	NULL
of	NULL
different	NULL
cell	NULL
types	NULL
including	NULL
freshly	NULL
isolated	NULL
lymphocytes	NULL
and	NULL
monocytes	NULL
.	NULL

Another	NULL
localization	NULL
was	NULL
found	NULL
in	NULL
the	NULL
cytosol	NULL
distinct	NULL
from	NULL
mitochondria	NULL
(	NULL
Fig	NULL
.	NULL

6	NULL
)	NULL
and	NULL
might	NULL
be	NULL
the	NULL
endoplasmic	NULL
reticulum	NULL
.	NULL

Pharmacological	NULL
Characterization	NULL
of	NULL
SR-BP-We	NULL
studied	NULL
the	NULL
binding	NULL
properties	NULL
of	NULL
human	NULL
SR-BP	NULL
expressed	NULL
in	NULL
yeast	NULL
and	NULL
compared	NULL
it	NULL
to	NULL
the	NULL
S.	NULL
cerevisice	NULL
ERG2	NULL
gene	NULL
product	NULL
(	NULL
Erg2p	NULL
)	NULL
.	NULL

Binding	NULL
assays	NULL
were	NULL
performed	NULL
in	NULL
transformed	NULL
cells	NULL
of	NULL
the	NULL
ERG2	NULL
disruptant	NULL
strain	NULL
EMY47	NULL
,	NULL
which	NULL
produce	NULL
either	NULL
Erg2p	NULL
(	NULL
control	NULL
)	NULL
or	NULL
SR-BP	NULL
.	NULL

SR	NULL
31747A	NULL
binding	NULL
assays	NULL
were	NULL
also	NULL
carried	NULL
out	NULL
on	NULL
purified	NULL
SR-BP	NULL
.	NULL

A	NULL
variety	NULL
of	NULL
competing	NULL
compounds	NULL
were	NULL
tested	NULL
,	NULL
including	NULL
drugs	NULL
with	NULL
high	NULL
affinity	NULL
for	NULL
sigma	NULL
receptors	NULL
as	NULL
well	NULL
as	NULL
compounds	NULL
known	NULL
to	NULL
bind	NULL
yeast	NULL
sterol	NULL
isomerase	NULL
(	NULL
Table	NULL
II	NULL
)	NULL
.	NULL

Among	NULL
the	NULL
various	NULL
molecules	NULL
tested	NULL
,	NULL
the	NULL
rank	NULL
order	NULL
of	NULL
drug	NULL
potency	NULL
at	NULL
SR	NULL
31747	NULL
sites	NULL
was	NULL
:	NULL
tridemorph	NULL
=	NULL
fenpropimorph	NULL
>	NULL
SR	NULL
31747A	NULL
>	NULL
haloperidol	NULL
>	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
>	NULL
ifenprodil	NULL
.	NULL

Purified	NULL
soluble	NULL
SR-BP	NULL
showed	NULL
an	NULL
essentially	NULL
similar	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
SR-BP	NULL
CP-SigmalR	NULL
S.cerevisiae	NULL
MQWAVGCRRWAWAALL	NULL
MOQWAVGRRWLWVALEF	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
LAVAAVLTQVVWLWL	NULL
LAAVAVLTQIVWLWL	NULL
CTOSFVFOREETAQL	NULL
ARQYACLDHELAFSR	NULL
LIVELRRLHPGHVLP	NULL
CGTONFVFOREETAQL	NULL
ARQYAGCLDHELAFSK	NULL
LIVELRRLHPVHVLP	NULL
U.maydis	NULL
M.grisea	NULL
N.crassa	NULL
SR-BP	NULL
GP-SigmalR	NULL
§.cerevisige	NULL
MKFFP	NULL
LLL-LIGVVGYIMNV	NULL
U.maydis	NULL
PRSNKAANGAS	NULL
--	NULL
--	NULL
--	NULL
-	NULL
TSPKRSWIIVSA	NULL
ALVGFCALIAALDSI	NULL
M.Grisea	NULL
-	NULL
-~	NULL
MSSPISGFLRFVA	NULL
VLLAVVSPLVYLAEQ	NULL
N.crassa	NULL
GSSGRSSSCSSCRCS	NULL
CRCRCSTGGWLKFFA	NULL
TLFALVAPIAYVLEQ	NULL
SR-BP	NULL
\	NULL
-	NULL
_	NULL
<	NULL
-c	NULL
--	NULL
c	NULL
--	NULL
--	NULL
--	NULL
-_-=	NULL
_o	NULL
--	NULL
-~-	NULL
QWVFVNAGG	NULL
WMGAMCLLHASLSEY	NULL
GP-SigMAIR	NULL
|	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-	NULL
--	NULL
--	NULL
--	NULL
QWVFVNAGG	NULL
WMGAMCLLHASLSEY	NULL
S.cerevisiae	NULL
ALASHYG-DEYINRY	NULL
--	NULL
-VKEEWVFNNAGG	NULL
AMGOMIILHASVSEY	NULL
U.	NULL
maydis	NULL
NLRADPELAPYINKN	NULL
HFSDESEWMFNNAGG	NULL
AMGSMFIIHASVTEY	NULL
M.grisea	NULL
ELRARPETTKYIS	NULL
--	NULL
--	NULL
-	NULL
VOEEWVENNAGG	NULL
AMGCMYTIIHASVTEY	NULL
N.crassa	NULL
ELNDRNGVAPYVN	NULL
--	NULL
--	NULL
-	NULL
NDEEWVENNAGG	NULL
AMGAMYIIHASITEY	NULL
SR-BP	NULL
GETVVHCPCEATAVE	NULL
WG	NULL
--	NULL
-PNIWMVEYCR	NULL
GVIPSTLAFALADTV	NULL
CP-SigmalR	NULL
GETVVEHCPCEATAVE	NULL
WG	NULL
--	NULL
-PNTWMVEYCR	NULL
GVIPSTLCFALADTV	NULL
S.cerevisiae	NULL
G	NULL
--	NULL
MTHHLKKGYAKQ	NULL
YSMP-GGSFALELAQ	NULL
GWIPCMLPFGFLDTF	NULL
U.maydis	NULL
G	NULL
--	NULL
SVEHLRRGTVEKQ	NULL
YMMPEDGCWALELAQ	NULL
GWTIPPMLPFGLADVL	NULL
M.grisea	NULL
G	NULL
--	NULL
SVEHLRRGTVKQ	NULL
YKMPE-GCFALEYAR	NULL
GWIPPMLFFGFADGL	NULL
N.	NULL
crassa	NULL
G	NULL
--	NULL
SVHELVRGTVKQ	NULL
YRMPE-SCFALEYPR	NULL
GWIPPMLFFGYADTL	NULL
LFTTWLPTNYMFDPK	NULL
R-SSF-~	NULL
--	NULL
-YIFDHK	NULL
RLESF-~	NULL
--	NULL
-YVFDHK	NULL
RLESF	NULL
--	NULL
--	NULL
YVFDTE	NULL
VLLFGTALGSRGHSG	NULL
VLLFGTALGSPRESG	NULL
LILFGTAVGTEGHTG	NULL
LIFFGTPVGTECGHTG	NULL
LIIFGTAIGTECGHTG	NULL
LIIFGTAIGTEGHTG	NULL
FSTODFLTELPYELRS	NULL
FSTODFLELPYPLRV	NULL
SSTLDLYPLYRTVYL	NULL
SSTLDLPTFGITVWLI	NULL
SSTLDFPTLHQTIVV	NULL
SSTLDFPTLWHRTSVI	NULL
TLNEICNSVISKHNA	NULL
ATYKTASTAVANHPG	NULL
HLHELSTOATAQHGN	NULL
HLHDLSKRAISRHGN	NULL
RYWAEISDTIISGTF	NULL
RYWAEISDTIISGTF	NULL
VHFADDYFTILHGTQ	NULL
RHTADDYFNILTGNQ	NULL
RHTADDYFNILTGEQ	NULL
RHTADDYFHILTGTQ	NULL
YARALQLELTTYLFG	NULL
TARDMGKNLLONKKF	NULL
TAREMVGNLLIGKF-TGREMLGNLMLGKEF-	NULL
27111	NULL
DEEL	NULL
--	NULL
--	NULL
--	NULL
--	NULL
--	NULL
-DEEL	NULL
--	NULL
~~	NULL
--	NULL
--	NULL
--	NULL
-	NULL
AEGLSTEDLLODVRD	NULL
==-~~NATATIFDDVLD	NULL
=-~-NTRAIVGHIVD	NULL
HOWREGTTXKSEVFYP	NULL
HOWREGTTKSEVFYP	NULL
IAALPYATEAEVYTP	NULL
YAFPAGALKAEHYPA	NULL
WAYVPGEYEPEVYPA	NULL
TAYVPGEYEPEVYPP	NULL
opp	NULL
oDp	NULL
223	NULL
223	NULL
222	NULL
241	NULL
221	NULL
255	NULL
Fic	NULL
.	NULL

4	NULL
.	NULL

Comparative	NULL
analysis	NULL
of	NULL
human	NULL
SR-BP	NULL
amino	NULL
acid	NULL
sequence	NULL
.	NULL

The	NULL
alignment	NULL
was	NULL
done	NULL
using	NULL
the	NULL
clustal	NULL
W	NULL
alignment	NULL
program	NULL
.	NULL

Identical	NULL
amino	NULL
acid	NULL
residues	NULL
conserved	NULL
in	NULL
three	NULL
or	NULL
more	NULL
sequences	NULL
are	NULL
in	NULL
bold	NULL
lefters	NULL
.	NULL

The	NULL
proteins	NULL
listed	NULL
include	NULL
the	NULL
SR-BP	NULL
,	NULL
the	NULL
guinea	NULL
pig	NULL
sigma	NULL
1	NULL
receptor	NULL
(	NULL
GP-sigma	NULL
IR	NULL
)	NULL
(	NULL
82	NULL
)	NULL
,	NULL
and	NULL
the	NULL
sterol	NULL
isomerase	NULL
from	NULL
the	NULL
yeast	NULL
(	NULL
S.	NULL
cerevisiae	NULL
)	NULL
(	NULL
84	NULL
)	NULL
,	NULL
the	NULL
rice	NULL
blast	NULL
fungus	NULL
M.	NULL
grisea	NULL
(	NULL
89	NULL
)	NULL
,	NULL
the	NULL
maize	NULL
smut	NULL
pathogen	NULL
U.	NULL
maydis	NULL
(	NULL
89	NULL
)	NULL
,	NULL
and	NULL
N.	NULL
crassa	NULL
(	NULL
GenBank	NULL
data	NULL
base	NULL
accession	NULL
number	NULL
222775	NULL
)	NULL
.	NULL

$	NULL
o	NULL
&	NULL
£	NULL
E	NULL
u	NULL
$	NULL
a	NULL
z	NULL
G	NULL
a	NULL
o	NULL
e	NULL
/\	NULL
g	NULL
g	NULL
5	NULL
§	NULL
g	NULL
E	NULL
ts	NULL
a	NULL
2	NULL
E	NULL
=	NULL
§§	NULL
$	NULL
Ps	NULL
G	NULL
§	NULL
£	NULL
o	NULL
5	NULL
%	NULL
%	NULL
g	NULL
9	NULL
o	NULL
_	NULL
o	NULL
§	NULL
6	NULL
>	NULL
x	NULL
S	NULL
a	NULL
a	NULL
2	NULL
P	NULL
8	NULL
2	NULL
&	NULL
o	NULL
o	NULL
``	NULL
A	NULL
@	NULL
T	NULL
m	NULL
a	NULL
1	NULL
G	NULL
4	NULL
¥	NULL
a	NULL
o	NULL
i-	NULL
a	NULL
F	NULL
O	NULL
m	NULL
0	NULL
a	NULL
kb	NULL
kb	NULL
75	NULL
7.5	NULL
Fig	NULL
.	NULL

5	NULL
.	NULL

Northern	NULL
blot	NULL
analysis	NULL
of	NULL
hu-	NULL
4.4	NULL
-I	NULL
man	NULL
SR-BP	NULL
expression	NULL
.	NULL

A	NULL
,	NULL
commercial	NULL
44	NULL
blots	NULL
(	NULL
CLONTECH	NULL
)	NULL
containing	NULL
2	NULL
ug	NULL
of	NULL
24	NULL
-I	NULL
24	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
®	NULL
mRNAs	NULL
from	NULL
human	NULL
tissues	NULL
[	NULL
T	NULL
.	NULL

*	NULL
©	NULL
*	NULL
M	NULL
“	NULL
tas	NULL
1.35	NULL
-I	NULL
LJ	NULL
shown	NULL
above	NULL
each	NULL
lane	NULL
were	NULL
hybridized	NULL
1.35	NULL
with	NULL
human	NULL
SR-BP	NULL
cDNA	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Blots	NULL
were	NULL
stripped	NULL
and	NULL
rehybridized	NULL
with	NULL
actin	NULL
probe	NULL
to	NULL
assess	NULL
levels	NULL
of	NULL
RNA	NULL
between	NULL
lanes	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

B	NULL
,	NULL
a	NULL
human	NULL
mas-	NULL
B	NULL
ter	NULL
blot	NULL
(	NULL
CLONTECH	NULL
)	NULL
containing	NULL
50	NULL
different	NULL
human	NULL
tissues	NULL
immobilized	NULL
in	NULL
sep-	NULL
1°	NULL
2	NULL
8	NULL
4	NULL
50	NULL
60	NULL
7	NULL
8	NULL
M	NULL
2	NULL
3	NULL
a	NULL
5	NULL
6	NULL
7	NULL
a	NULL
arate	NULL
dots	NULL
was	NULL
hyandlzed	NULL
with	NULL
humaIn	NULL
A	NULL
R	NULL
A	NULL
|	NULL
cautare	NULL
|	NULL
ows	NULL
eous	NULL
SR-BP	NULL
cDNA	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materi-	NULL
ad	NULL
mess	NULL
*t	NULL
aes	NULL
als	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
diagram	NULL
on	NULL
.	NULL

tIhe	NULL
left	NULL
B	NULL
¥	NULL
R	NULL
M	NULL
k	NULL
€	NULL
B	NULL
|	NULL
g	NULL
@	NULL
10	NULL
!	NULL

|	NULL
putamen	NULL
|	NULL
supstantal	NULL
temporal	NULL
|	NULL
thatamus	NULL
|ssepstame	NULL
|	NULL
spinal	NULL
shows	NULL
Eh	NULL
e	NULL
nature	NULL
and	NULL
the	NULL
position	NULL
of	NULL
C	NULL
|	NULL
neat	NULL
|	NULL
acria	NULL
|	NULL
SHR	NULL
!	NULL

|	NULL
colon	NULL
|	NULL
btadder	NULL
|	NULL
uterus	NULL
|	NULL
prostate	NULL
|	NULL
stomach	NULL
poly	NULL
(	NULL
A	NULL
)	NULL
``	NULL
RNAs	NULL
and	NULL
controls	NULL
.	NULL

c	NULL
|	NULL
.	NULL

&	NULL
k	NULL
%	NULL
%	NULL
¥	NULL
%	NULL
eusds	NULL
D	NULL
|	NULL
wsis	NULL
|	NULL
ovary	NULL
|pancieas	NULL
|	NULL
pautay	NULL
|	NULL
egen	NULL
!	NULL

|	NULL
|	NULL
setvay	NULL
o	NULL
me	NULL
mn	NULL
-	NULL
%	NULL
®	NULL
m	NULL
oan	NULL
Ae	NULL
®	NULL
g	NULL
|	NULL
worey	NULL
|	NULL
wer	NULL
|	NULL
wiith	NULL
,	NULL
|	NULL
seen	NULL
|	NULL
tyme	NULL
(	NULL
IRE	NULL
|	NULL
490	NULL
|	NULL
oie	NULL
,	NULL
E	NULL
#	NULL
©	NULL
L	NULL
a	NULL
#	NULL
*	NULL
®	NULL
F|	NULL
appentic	NULL
|	NULL
-	NULL
tung	NULL
-|	NULL
trachea	NULL
|	NULL
placenta	NULL
cole	NULL
#	NULL
a	NULL
®	NULL
a	NULL
|	NULL
Sh	NULL
|	NULL
MB	NULL
|	NULL
ud	NULL
,	NULL
|	NULL
ME	NULL
|	NULL
spin	NULL
|	NULL
wine	NULL
|	NULL
(	NULL
ag	NULL
c	NULL
@	NULL
¥	NULL
%	NULL
*+	NULL
%	NULL
8	NULL
loltial	NULL
GA	NULL
|	NULL
hi	NULL
|	NULL
6G	NULL
(	NULL
cen	NULL
)	NULL
``	NULL
ons	NULL
|	NULL
``	NULL
ORA	NULL
H	NULL
affinity	NULL
profile	NULL
for	NULL
various	NULL
tested	NULL
compounds	NULL
when	NULL
compared	NULL
with	NULL
membraneous	NULL
SR-BP	NULL
.	NULL

Only	NULL
minor	NULL
decreases	NULL
in	NULL
affinity	NULL
were	NULL
observed	NULL
for	NULL
haloperidol	NULL
and	NULL
ifenprodil	NULL
,	NULL
instead	NULL
of	NULL
major	NULL
decreases	NULL
for	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
,	NULL
which	NULL
could	NULL
be	NULL
related	NULL
to	NULL
a	NULL
difference	NULL
in	NULL
protein	NULL
conformation	NULL
.	NULL

Comparable	NULL
ranking	NULL
of	NULL
tested	NULL
ligands	NULL
was	NULL
observed	NULL
with	NULL
Erg2p	NULL
:	NULL
tridemorph	NULL
=	NULL
fenpropimorph	NULL
>	NULL
haloperidol	NULL
>	NULL
SR	NULL
31747A	NULL
>	NULL
ifenprodil	NULL
.	NULL

Nevertheless	NULL
,	NULL
a	NULL
major	NULL
difference	NULL
in	NULL
the	NULL
pharmacology	NULL
of	NULL
SR-BP	NULL
and	NULL
Erg2p	NULL
is	NULL
that	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
inhibited	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
JSR	NULL
31747A	NULL
to	NULL
SR-BP	NULL
(	NULL
IC	NULL
;	NULL
,	NULL
=	NULL
18	NULL
nM	NULL
)	NULL
but	NULL
not	NULL
to	NULL
Erg2p	NULL
(	NULL
IC	NULL
;	NULL
;	NULL
,	NULL
>	NULL
1000	NULL
nx	NULL
)	NULL
.	NULL

We	NULL
therefore	NULL
examined	NULL
the	NULL
binding	NULL
of	NULL
[	NULL
*H	NULL
]	NULL
pentazocine	NULL
to	NULL
Erg2p	NULL
and	NULL
SR-BP	NULL
.	NULL

In	NULL
agreement	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
27112	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
anti-SR-BP	NULL
Ab	NULL
anti-nuclear	NULL
mb	NULL
Ab	NULL
emerged	NULL
images	NULL
FiG	NULL
.	NULL

6	NULL
.	NULL

Nuclear	NULL
envelope	NULL
localization	NULL
of	NULL
SR-BP	NULL
in	NULL
THP1	NULL
cells	NULL
by	NULL
confocal	NULL
microscopy	NULL
.	NULL

THP1	NULL
cells	NULL
were	NULL
simultaneously	NULL
labeled	NULL
with	NULL
anti-SR-BP	NULL
and	NULL
anti-nuclear	NULL
envelope	NULL
mAbs	NULL
or	NULL
with	NULL
anti-SR-BP	NULL
and	NULL
anti-mitochondria	NULL
(	NULL
anfi-m£	NULL
)	NULL
mAbs	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
red	NULL
(	NULL
Cy5	NULL
)	NULL
left	NULL
side	NULL
corresponds	NULL
to	NULL
the	NULL
labeling	NULL
of	NULL
SR-BP	NULL
,	NULL
the	NULL
green	NULL
(	NULL
fluorescein	NULL
isothiocyanate	NULL
)	NULL
central	NULL
part	NULL
to	NULL
the	NULL
labeling	NULL
of	NULL
subcellular	NULL
organelles	NULL
,	NULL
and	NULL
the	NULL
right	NULL
side	NULL
represents	NULL
the	NULL
merged	NULL
images	NULL
.	NULL

A	NULL
single	NULL
optical	NULL
section	NULL
representative	NULL
of	NULL
each	NULL
cell	NULL
type	NULL
is	NULL
shown	NULL
in	NULL
this	NULL
image	NULL
.	NULL

Ab	NULL
,	NULL
antibody	NULL
;	NULL
mb	NULL
,	NULL
membrane	NULL
.	NULL

anti-SR-BP	NULL
Ab	NULL
anti-mt	NULL
Ab	NULL
emerged	NULL
images	NULL
TaBLE	NULL
II	NULL
Inhibition	NULL
of	NULL
[	NULL
PHJSR	NULL
31747	NULL
or	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
binding	NULL
to	NULL
soluble	NULL
SR-BP	NULL
,	NULL
SR-BP	NULL
,	NULL
and	NULL
Erg2p	NULL
expressed	NULL
in	NULL
yeast	NULL
by	NULL
different	NULL
drugs	NULL
Binding	NULL
experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

The	NULL
values	NULL
shown	NULL
are	NULL
the	NULL
mean	NULL
+	NULL
S.E	NULL
.	NULL

of	NULL
triplicate	NULL
determinations	NULL
.	NULL

Data	NULL
are	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
two	NULL
or	NULL
three	NULL
.	NULL

Binding	NULL
parameters	NULL
were	NULL
obtained	NULL
by	NULL
nonlinear	NULL
curve	NULL
fitting	NULL
of	NULL
the	NULL
inhibition	NULL
data	NULL
to	NULL
the	NULL
general	NULL
dose-response	NULL
equation	NULL
(	NULL
41	NULL
)	NULL
.	NULL

ICs	NULL
,	NULL
(	NULL
om	NULL
)	NULL
Compounds	NULL
317474	NULL
Yeast	NULL
PHISR	NULL
Yeast	NULL
Erg2p	NULL
site	NULL
soluble	NULL
SR-	NULL
31747A	NULL
site	NULL
SR-	NULL
CH	NULL
]	NULL
-pentazocine	NULL
°H	NULL
]	NULL
-SR	NULL
317474	NULL
BP	NULL
BP	NULL
site	NULL
SR-BP	NULL
site	NULL
SR	NULL
31747A	NULL
1.5	NULL
+	NULL
0.3	NULL
1.7	NULL
+	NULL
0.1	NULL
0.90	NULL
+	NULL
0.02	NULL
2.8	NULL
+	NULL
0.2	NULL
Emopamil	NULL
258	NULL
+	NULL
12	NULL
1000	NULL
190	NULL
+	NULL
39	NULL
>	NULL
1000	NULL
Ifenprodil	NULL
333	NULL
+	NULL
50	NULL
70	NULL
+	NULL
5	NULL
16	NULL
+	NULL
1	NULL
16	NULL
+	NULL
2	NULL
Fenpropimorph	NULL
2.6	NULL
+	NULL
0.2	NULL
0.17	NULL
+	NULL
0.02	NULL
0.50	NULL
+	NULL
0.04	NULL
0.10	NULL
+	NULL
0.01	NULL
Tridemorph	NULL
0.7	NULL
+	NULL
0.04	NULL
0.16	NULL
+	NULL
0.01	NULL
0.91	NULL
+	NULL
0.07	NULL
0.18	NULL
+	NULL
0.01	NULL
(	NULL
+	NULL
)	NULL
-Pentazocine	NULL
1000	NULL
18	NULL
+	NULL
2	NULL
6.6	NULL
+	NULL
1.3	NULL
>	NULL
1000	NULL
(	NULL
-	NULL
)	NULL
-Pentazocine	NULL
10,000	NULL
>	NULL
1000	NULL
290	NULL
+	NULL
20	NULL
>	NULL
1000	NULL
DTG	NULL
2000	NULL
>	NULL
1000	NULL
92	NULL
+	NULL
15	NULL
>	NULL
10,000	NULL
(	NULL
+	NULL
)	NULL
-83-PPP	NULL
1000	NULL
>	NULL
1000	NULL
176	NULL
+	NULL
19	NULL
>	NULL
1000	NULL
(	NULL
+	NULL
)	NULL
SKF10047	NULL
5000	NULL
>	NULL
1000	NULL
310	NULL
+	NULL
58	NULL
>	NULL
1000	NULL
(	NULL
-	NULL
)	NULL
SKF10047	NULL
>	NULL
10,000	NULL
>	NULL
1000	NULL
>	NULL
10,000	NULL
>	NULL
1000	NULL
Haloperidol	NULL
63	NULL
+	NULL
2	NULL
5.3	NULL
+	NULL
0.5	NULL
1.2	NULL
+	NULL
0.1	NULL
1.3	NULL
+	NULL
0.1	NULL
with	NULL
the	NULL
above	NULL
findings	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
pentazocine	NULL
,	NULL
which	NULL
bound	NULL
to	NULL
membraneous	NULL
SR-BP	NULL
,	NULL
did	NULL
not	NULL
bind	NULL
to	NULL
Erg2p	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Table	NULL
II	NULL
,	NULL
the	NULL
binding	NULL
profile	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
pentazocine	NULL
to	NULL
membraneous	NULL
SR-BP	NULL
corresponded	NULL
to	NULL
a	NULL
typical	NULL
sigma	NULL
1	NULL
profile	NULL
:	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-SKF	NULL
10,047	NULL
having	NULL
,	NULL
respectively	NULL
,	NULL
a	NULL
43-fold	NULL
and	NULL
>	NULL
33-fold	NULL
higher	NULL
affinity	NULL
than	NULL
their	NULL
(	NULL
-	NULL
)	NULL
-counterparts	NULL
.	NULL

Unlike	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
and	NULL
haloperidol	NULL
,	NULL
the	NULL
sigma	NULL
ligands	NULL
1,3-di	NULL
(	NULL
2-tolyl	NULL
)	NULL
guanidine	NULL
,	NULL
(	NULL
+	NULL
)	NULL
-3-PPP	NULL
,	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-SKF	NULL
10,047	NULL
were	NULL
unable	NULL
to	NULL
displace	NULL
[	NULL
°HJSR	NULL
31747A	NULL
.	NULL

We	NULL
also	NULL
noted	NULL
a	NULL
low	NULL
efficiency	NULL
of	NULL
inhibition	NULL
in	NULL
the	NULL
case	NULL
of	NULL
the	NULL
sigma	NULL
1	NULL
ligand	NULL
emopamil	NULL
.	NULL

Scatchard	NULL
plot	NULL
analysis	NULL
(	NULL
Fig	NULL
.	NULL

7A	NULL
)	NULL
for	NULL
membraneous	NULL
SR-BP	NULL
using	NULL
[	NULL
PHJSR	NULL
31747A	NULL
as	NULL
labeled	NULL
ligand	NULL
revealed	NULL
a	NULL
single	NULL
high	NULL
affinity	NULL
site	NULL
with	NULL
a	NULL
K	NULL
,	NULL
value	NULL
of	NULL
0.15	NULL
nm	NULL
and	NULL
a	NULL
B	NULL
,	NULL
,	NULL
,	NULL
,	NULL
of	NULL
6195	NULL
fmol/mg	NULL
protein	NULL
.	NULL

In	NULL
these	NULL
experiments	NULL
,	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
acted	NULL
as	NULL
a	NULL
competitive	NULL
ligand	NULL
(	NULL
increased	NULL
K	NULL
,	NULL
with	NULL
unchanged	NULL
B	NULL
,	NULL
,	NULL
,	NULL
)	NULL
.	NULL

Comparatively	NULL
,	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
(	NULL
Fig	NULL
.	NULL

7B	NULL
)	NULL
bound	NULL
with	NULL
high	NULL
affinity	NULL
to	NULL
a	NULL
single	NULL
population	NULL
of	NULL
sites	NULL
(	NULL
K	NULL
,	NULL
,	NULL
=	NULL
7.1	NULL
nM	NULL
and	NULL
B	NULL
,	NULL
,	NULL
,	NULL
,	NULL
=	NULL
3860	NULL
fmol/mg	NULL
protein	NULL
)	NULL
.	NULL

SR	NULL
31747A	NULL
used	NULL
at	NULL
the	NULL
concentration	NULL
of	NULL
2	NULL
nM	NULL
was	NULL
competitive	NULL
to	NULL
this	NULL
site	NULL
(	NULL
K	NULL
,	NULL
=	NULL
11.7	NULL
nm	NULL
and	NULL
Bu..	NULL
,	NULL
=	NULL
3977	NULL
fmol/mg	NULL
protein	NULL
)	NULL
.	NULL

The	NULL
affinity	NULL
of	NULL
[	NULL
PHJSR	NULL
31747A	NULL
for	NULL
the	NULL
SR-BP	NULL
site	NULL
was	NULL
50-	NULL
fold	NULL
higher	NULL
compared	NULL
with	NULL
that	NULL
of	NULL
[	NULL
PH	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
previously	NULL
(	NULL
14	NULL
)	NULL
that	NULL
SR	NULL
31747	NULL
is	NULL
active	NULL
at	NULL
inhibiting	NULL
lymphocyte	NULL
proliferation	NULL
while	NULL
pentazocine	NULL
is	NULL
inac-tive	NULL
.	NULL

Since	NULL
pentazocine	NULL
does	NULL
not	NULL
block	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
while	NULL
it	NULL
prevents	NULL
[	NULL
°HJSR	NULL
31747A	NULL
binding	NULL
,	NULL
if	NULL
SR	NULL
31747A	NULL
is	NULL
acting	NULL
through	NULL
SR-BP	NULL
to	NULL
block	NULL
T	NULL
lymphocyte	NULL
mitogenesis	NULL
,	NULL
pentazocine	NULL
should	NULL
thereby	NULL
prevent	NULL
SR	NULL
31747	NULL
inhibition	NULL
.	NULL

We	NULL
hence	NULL
analyzed	NULL
the	NULL
effect	NULL
of	NULL
SR	NULL
31747	NULL
on	NULL
cell	NULL
growth	NULL
in	NULL
the	NULL
absence	NULL
or	NULL
presence	NULL
of	NULL
pentazocine	NULL
.	NULL

As	NULL
shown	NULL
in	NULL
Fig	NULL
.	NULL

8A	NULL
,	NULL
cellular	NULL
proliferation	NULL
was	NULL
inhibited	NULL
by	NULL
SR	NULL
31747	NULL
and	NULL
restored	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
increasing	NULL
pentazocine	NULL
concentrations	NULL
(	NULL
Fig	NULL
.	NULL

8B	NULL
)	NULL
.	NULL

Although	NULL
it	NULL
is	NULL
not	NULL
known	NULL
whether	NULL
pentazocine	NULL
could	NULL
completely	NULL
reverse	NULL
the	NULL
SR	NULL
31747	NULL
effect	NULL
due	NULL
to	NULL
the	NULL
high	NULL
pentazocine	NULL
concentration-induced	NULL
toxicity	NULL
,	NULL
this	NULL
observation	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
SR	NULL
31747A	NULL
antiproliferative	NULL
effects	NULL
could	NULL
be	NULL
mediated	NULL
by	NULL
SR-BP	NULL
.	NULL

DISCUSSION	NULL
SR	NULL
31747	NULL
is	NULL
an	NULL
immunomodulating	NULL
agent	NULL
eliciting	NULL
high	NULL
affinity	NULL
for	NULL
sigma	NULL
receptors	NULL
.	NULL

It	NULL
demonstrates	NULL
immunosuppressive	NULL
properties	NULL
both	NULL
in	NULL
vitro	NULL
and	NULL
in	NULL
vivo	NULL
(	NULL
14	NULL
)	NULL
.	NULL

This	NULL
compound	NULL
,	NULL
which	NULL
blocks	NULL
the	NULL
proliferation	NULL
of	NULL
lymphocytes	NULL
at	NULL
nanomolar	NULL
concentrations	NULL
,	NULL
displays	NULL
a	NULL
spectrum	NULL
of	NULL
activity	NULL
distinct	NULL
from	NULL
current	NULL
immunosuppressive	NULL
agents	NULL
(	NULL
35	NULL
)	NULL
.	NULL

However	NULL
,	NULL
these	NULL
stud	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
40000	NULL
g	NULL
30000	NULL
IL	NULL
.	NULL

3	NULL
&	NULL
3	NULL
3	NULL
e	NULL
20000	NULL
'	NULL
o	NULL
©	NULL
a	NULL
.	NULL

D	NULL
10000	NULL
-	NULL
o	NULL
``	NULL
m-	NULL
o	NULL
L	NULL
~	NULL
``	NULL
C	NULL
%	NULL
8	NULL
``	NULL
u	NULL
im	NULL
)	NULL
wt..	NULL
0	NULL
``	NULL
T	NULL
T	NULL
T	NULL
T	NULL
T	NULL
0	NULL
2000	NULL
4000	NULL
6000	NULL
Specific	NULL
bound	NULL
(	NULL
fmol/mg	NULL
prot	NULL
.	NULL
)	NULL

B	NULL
soo	NULL
-	NULL
5	NULL
400	NULL
Specific	NULL
bound	NULL
/	NULL
Free	NULL
200	NULL
0	NULL
a	NULL
|	NULL
t	NULL
1	NULL
t	NULL
|	NULL
0	NULL
1000	NULL
2000	NULL
3000	NULL
Specific	NULL
bound	NULL
(	NULL
fmol/mg	NULL
prot	NULL
.	NULL
)	NULL

I	NULL
4000	NULL
Fig	NULL
.	NULL

7	NULL
.	NULL

A	NULL
,	NULL
Scatchard	NULL
plots	NULL
of	NULL
[	NULL
°HJSR	NULL
$	NULL
1747A	NULL
binding	NULL
to	NULL
membraneous	NULL
SR-BP	NULL
without	NULL
or	NULL
with	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

Yeast	NULL
membranes	NULL
(	NULL
15	NULL
pg/as-say	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
[	NULL
°HJSR	NULL
31747	NULL
(	NULL
0.03-8	NULL
nM	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
]	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
(	NULL
25	NULL
nM	NULL
;	NULL
RID	NULL
.	NULL

Experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Each	NULL
value	NULL
is	NULL
represented	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
determinations	NULL
.	NULL

Data	NULL
are	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
the	NULL
Scatchard	NULL
transformation	NULL
of	NULL
these	NULL
data	NULL
.	NULL

The	NULL
K	NULL
,	NULL
and	NULL
B	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
,	NULL
values	NULL
are	NULL
for	NULL
control	NULL
0.15	NULL
+	NULL
0.01	NULL
(	NULL
n	NULL
[	NULL
seapm	NULL
)	NULL
and	NULL
6195	NULL
+	NULL
121	NULL
(	NULL
fmol/mg	NULL
proteins	NULL
)	NULL
,	NULL
respectively	NULL
;	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
25	NULL
nM	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
0.32	NULL
+	NULL
0.01	NULL
(	NULL
n	NULL
[	NULL
scapm	NULL
)	NULL
and	NULL
5580	NULL
+	NULL
94	NULL
(	NULL
fmol/mg	NULL
proteins	NULL
)	NULL
.	NULL

B	NULL
:	NULL
Scatchard	NULL
plots	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
binding	NULL
to	NULL
human	NULL
SR-BP	NULL
without	NULL
or	NULL
with	NULL
SR	NULL
31747A	NULL
.	NULL

Yeast	NULL
membranes	NULL
(	NULL
50	NULL
ug/assay	NULL
)	NULL
were	NULL
incubated	NULL
with	NULL
increasing	NULL
concentrations	NULL
of	NULL
[	NULL
°H	NULL
]	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
(	NULL
0.02-20	NULL
nM	NULL
)	NULL
in	NULL
the	NULL
absence	NULL
(	NULL
]	NULL
)	NULL
or	NULL
presence	NULL
of	NULL
SR	NULL
31747A	NULL
(	NULL
2	NULL
nM	NULL
;	NULL
M.	NULL
Experiments	NULL
were	NULL
performed	NULL
as	NULL
described	NULL
under	NULL
``	NULL
Materials	NULL
and	NULL
Methods	NULL
.	NULL
``	NULL

Each	NULL
value	NULL
is	NULL
represented	NULL
as	NULL
the	NULL
mean	NULL
of	NULL
triplicate	NULL
determinations	NULL
.	NULL

Data	NULL
are	NULL
from	NULL
one	NULL
representative	NULL
experiment	NULL
out	NULL
of	NULL
three	NULL
performed	NULL
in	NULL
triplicate	NULL
.	NULL

The	NULL
figure	NULL
shows	NULL
the	NULL
Scatchard	NULL
transformation	NULL
of	NULL
these	NULL
data	NULL
.	NULL

The	NULL
K	NULL
,	NULL
,	NULL
and	NULL
B	NULL
,	NULL
,	NULL
...	NULL
.	NULL

values	NULL
are	NULL
for	NULL
control	NULL
7.1	NULL
+	NULL
0.4	NULL
(	NULL
n	NULL
[	NULL
seapm	NULL
)	NULL
and	NULL
3860	NULL
+	NULL
126	NULL
(	NULL
fmol/mg	NULL
proteins	NULL
)	NULL
respectively	NULL
;	NULL
and	NULL
in	NULL
the	NULL
presence	NULL
of	NULL
2	NULL
nM	NULL
SR	NULL
31747A	NULL
,	NULL
11.7	NULL
+	NULL
0.01	NULL
(	NULL
n	NULL
[	NULL
scapm	NULL
)	NULL
and	NULL
8977	NULL
+	NULL
182	NULL
(	NULL
fmol/mg	NULL
proteins	NULL
)	NULL
.	NULL

27113	NULL
A	NULL
€	NULL
C	NULL
o	NULL
O	NULL
6	NULL
£	NULL
Fo	NULL
g	NULL
F	NULL
@	NULL
.	NULL

40	NULL
3	NULL
C	NULL
§	NULL
E	NULL
,	NULL
20	NULL
{	NULL
e	NULL
€	NULL
{	NULL
o	NULL
0	NULL
``	NULL
I	NULL
'	NULL
t	NULL
CUT	NULL
ious	NULL
an	NULL
au	NULL
a	NULL
aan	NULL
``	NULL
mum	NULL
1	NULL
10	NULL
100	NULL
1000	NULL
Concentrations	NULL
(	NULL
nM	NULL
)	NULL
B	NULL
€	NULL
co	NULL
5	NULL
r=	NULL
0.974	NULL
8	NULL
so	NULL
a	NULL
'D	NULL
&	NULL
40	NULL
R.	NULL
z	NULL
30	NULL
|_|	NULL
[	NULL
+l	NULL
#	NULL
20	NULL
©	NULL
5	NULL
10	NULL
8	NULL
0+	NULL
r	NULL
=	NULL
--	NULL
--	NULL
--	NULL
--	NULL
r	NULL
£	NULL
10	NULL
100	NULL
(	NULL
+	NULL
)	NULL
-	NULL
pentazocine	NULL
(	NULL
nM	NULL
)	NULL
Fic	NULL
.	NULL

8	NULL
.	NULL

Effect	NULL
of	NULL
pentazocine	NULL
on	NULL
the	NULL
inhibition	NULL
of	NULL
T	NULL
lymphocyte	NULL
mitogenesis	NULL
by	NULL
SR	NULL
31747	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
isolated	NULL
from	NULL
naive	NULL
BALB/c	NULL
mice	NULL
and	NULL
cultured	NULL
(	NULL
4	NULL
X	NULL
10°/well	NULL
)	NULL
for	NULL
96	NULL
h	NULL
with	NULL
1	NULL
ug/ml	NULL
staphylococcal	NULL
enterotoxin	NULL
B	NULL
.	NULL

[	NULL
°H	NULL
]	NULL
thymidine	NULL
was	NULL
incorporated	NULL
during	NULL
the	NULL
last	NULL
4	NULL
h.	NULL
A	NULL
,	NULL
effect	NULL
of	NULL
SR	NULL
31747A	NULL
(	NULL
@	NULL
)	NULL
or	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
(	NULL
¥	NULL
)	NULL
on	NULL
cell	NULL
proliferation	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
[	NULL
H	NULL
]	NULL
thymidine	NULL
incorporation	NULL
of	NULL
untreated	NULL
cells	NULL
(	NULL
100	NULL
%	NULL
=	NULL
64983	NULL
cpm	NULL
)	NULL
.	NULL

B	NULL
,	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
blocked	NULL
the	NULL
inhibitory	NULL
effect	NULL
induced	NULL
by	NULL
SR	NULL
31747A	NULL
.	NULL

Spleen	NULL
cells	NULL
were	NULL
treated	NULL
with	NULL
27	NULL
nm	NULL
SR	NULL
31747	NULL
and	NULL
with	NULL
various	NULL
concentrations	NULL
of	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

Results	NULL
are	NULL
expressed	NULL
as	NULL
the	NULL
percent	NULL
of	NULL
inhibition	NULL
of	NULL
SR	NULL
81747A	NULL
effect	NULL
.	NULL

ies	NULL
suffered	NULL
from	NULL
a	NULL
lack	NULL
of	NULL
information	NULL
on	NULL
the	NULL
binding	NULL
protein	NULL
involved	NULL
to	NULL
relate	NULL
the	NULL
observed	NULL
effects	NULL
to	NULL
a	NULL
biochemical	NULL
process	NULL
(	NULL
36	NULL
)	NULL
.	NULL

In	NULL
an	NULL
attempt	NULL
to	NULL
decipher	NULL
this	NULL
,	NULL
we	NULL
have	NULL
purified	NULL
,	NULL
cloned	NULL
,	NULL
sequenced	NULL
,	NULL
and	NULL
expressed	NULL
the	NULL
SR-BP	NULL
.	NULL

We	NULL
also	NULL
studied	NULL
the	NULL
tissue	NULL
distribution	NULL
,	NULL
subcellular	NULL
localization	NULL
,	NULL
and	NULL
pharmacological	NULL
properties	NULL
of	NULL
this	NULL
protein	NULL
.	NULL

Molecular	NULL
Characterization	NULL
of	NULL
SR-BP-Partial	NULL
purification	NULL
of	NULL
the	NULL
digitonin-solubilized	NULL
SR-BP	NULL
from	NULL
cells	NULL
of	NULL
the	NULL
human	NULL
T	NULL
leukemic	NULL
Ichikawa	NULL
cell	NULL
line	NULL
was	NULL
achieved	NULL
by	NULL
three	NULL
successive	NULL
ion-exchange	NULL
chromatographic	NULL
steps	NULL
followed	NULL
by	NULL
a	NULL
gel	NULL
filtra-tion	NULL
.	NULL

The	NULL
specific	NULL
activity	NULL
obtained	NULL
was	NULL
510	NULL
pmol/mg	NULL
of	NULL
protein	NULL
,	NULL
representing	NULL
a	NULL
160-fold	NULL
increase	NULL
over	NULL
the	NULL
specific	NULL
activity	NULL
of	NULL
the	NULL
crude	NULL
extract	NULL
.	NULL

This	NULL
preparation	NULL
was	NULL
used	NULL
to	NULL
generate	NULL
a	NULL
monoclonal	NULL
antibody	NULL
anti-SR-BP	NULL
,	NULL
which	NULL
in	NULL
turn	NULL
enabled	NULL
the	NULL
subsequent	NULL
purification	NULL
of	NULL
SR-BP	NULL
.	NULL

Immunopurified	NULL
SR-BP	NULL
was	NULL
used	NULL
for	NULL
partial	NULL
amino	NULL
acid	NULL
sequence	NULL
analyses	NULL
,	NULL
after	NULL
which	NULL
the	NULL
corresponding	NULL
cDNA	NULL
was	NULL
cloned	NULL
.	NULL

The	NULL
nucleotide	NULL
sequence	NULL
of	NULL
the	NULL
SR-BP	NULL
cDNA	NULL
encodes	NULL
a	NULL
223-amino	NULL
acid	NULL
protein	NULL
.	NULL

Furthermore	NULL
,	NULL
the	NULL
characterization	NULL
of	NULL
the	NULL
heterologous	NULL
expression	NULL
of	NULL
the	NULL
SR-BP	NULL
cDNA	NULL
in	NULL
yeast	NULL
demonstrates	NULL
that	NULL
the	NULL
cloned	NULL
cDNA	NULL
encodes	NULL
a	NULL
protein	NULL
that	NULL
has	NULL
a	NULL
high	NULL
affinity	NULL
[	NULL
°HJSR	NULL
31747A-binding	NULL
domain	NULL
and	NULL
is	NULL
specifically	NULL
recognized	NULL
by	NULL
anti	NULL
SR-BP-antibodies	NULL
.	NULL

In	NULL
the	NULL
course	NULL
of	NULL
this	NULL
study	NULL
,	NULL
we	NULL
cloned	NULL
the	NULL
guinea	NULL
pig	NULL
and	NULL
human	NULL
sigma	NULL
1	NULL
receptor	NULL
cDNA	NULL
and	NULL
found	NULL
a	NULL
93	NULL
%	NULL
and	NULL
100	NULL
%	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
27114	NULL
amino	NULL
acid	NULL
sequence	NULL
identity	NULL
,	NULL
respectively	NULL
,	NULL
with	NULL
SR-BP	NULL
(	NULL
82	NULL
,	NULL
33	NULL
)	NULL
.	NULL

We	NULL
discuss	NULL
below	NULL
successively	NULL
(	NULL
i	NULL
)	NULL
the	NULL
relationship	NULL
of	NULL
SR-BP	NULL
and	NULL
sigma	NULL
1	NULL
receptor	NULL
,	NULL
and	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
relationship	NULL
of	NULL
SR-BP	NULL
and	NULL
Erg2p	NULL
.	NULL

Comparison	NULL
of	NULL
SR-BP	NULL
and	NULL
Sigma	NULL
1	NULL
Receptor-The	NULL
sigma	NULL
1	NULL
receptor	NULL
was	NULL
recently	NULL
purified	NULL
and	NULL
characterized	NULL
from	NULL
guinea	NULL
pig	NULL
liver	NULL
by	NULL
Hanner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
82	NULL
)	NULL
(	NULL
see	NULL
,	NULL
for	NULL
review	NULL
,	NULL
Moebius	NULL
et	NULL
al	NULL
.	NULL

(	NULL
37	NULL
)	NULL
)	NULL
.	NULL

The	NULL
high	NULL
degree	NULL
of	NULL
homology	NULL
between	NULL
the	NULL
two	NULL
proteins	NULL
suggests	NULL
that	NULL
it	NULL
could	NULL
be	NULL
the	NULL
guinea	NULL
pig	NULL
counterpart	NULL
of	NULL
human	NULL
SR-BP	NULL
.	NULL

We	NULL
show	NULL
here	NULL
that	NULL
the	NULL
SR	NULL
31747	NULL
binding	NULL
profile	NULL
fits	NULL
with	NULL
the	NULL
pharmacological	NULL
definition	NULL
of	NULL
sigma	NULL
1	NULL
receptor	NULL
:	NULL
1	NULL
)	NULL
SR-BP	NULL
binds	NULL
the	NULL
sigma	NULL
ligands	NULL
,	NULL
pentazocine	NULL
and	NULL
haloperidol	NULL
with	NULL
high	NULL
affinity	NULL
;	NULL
2	NULL
)	NULL
only	NULL
one	NULL
stereoisomer	NULL
of	NULL
pentazocine	NULL
efficiently	NULL
competed	NULL
for	NULL
[	NULL
PH	NULL
]	NULL
JSR	NULL
31747A-labeled	NULL
sites	NULL
,	NULL
which	NULL
is	NULL
a	NULL
trait	NULL
characteristic	NULL
of	NULL
the	NULL
sigma	NULL
1	NULL
receptor	NULL
previously	NULL
characterized	NULL
in	NULL
rat	NULL
spleen	NULL
(	NULL
10	NULL
,	NULL
11	NULL
,	NULL
12	NULL
)	NULL
.	NULL

Our	NULL
results	NULL
obtained	NULL
with	NULL
®H	NULL
]	NULL
pentazocine	NULL
are	NULL
in	NULL
line	NULL
with	NULL
those	NULL
of	NULL
Hanner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
on	NULL
the	NULL
sigma	NULL
1	NULL
receptor	NULL
from	NULL
guinea	NULL
pig	NULL
.	NULL

From	NULL
saturation	NULL
studies	NULL
with	NULL
SR	NULL
31747	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
binding	NULL
on	NULL
SR-BP	NULL
,	NULL
we	NULL
concluded	NULL
that	NULL
both	NULL
ligands	NULL
bound	NULL
to	NULL
a	NULL
single	NULL
population	NULL
of	NULL
sites	NULL
.	NULL

As	NULL
SR	NULL
31747A	NULL
was	NULL
competitively	NULL
displaced	NULL
by	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
and	NULL
reciprocally	NULL
,	NULL
it	NULL
is	NULL
very	NULL
likely	NULL
that	NULL
SR	NULL
31747A	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
bind	NULL
the	NULL
same	NULL
site	NULL
.	NULL

Nevertheless	NULL
,	NULL
B	NULL
,	NULL
,	NULL
,	NULL
,	NULL
values	NULL
(	NULL
6195	NULL
and	NULL
3860	NULL
fmol/mg	NULL
proteins	NULL
for	NULL
SR	NULL
31747A	NULL
and	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
,	NULL
respectively	NULL
)	NULL
were	NULL
slightly	NULL
different	NULL
and	NULL
the	NULL
SR	NULL
31747	NULL
affinity	NULL
was	NULL
50-fold	NULL
higher	NULL
than	NULL
that	NULL
of	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

We	NULL
observed	NULL
an	NULL
irreversible	NULL
(	NULL
or	NULL
very	NULL
slowly	NULL
dissociable	NULL
)	NULL
binding	NULL
of	NULL
[	NULL
PHJSR	NULL
31747A	NULL
at	NULL
SR-BP	NULL
.	NULL

Comparison	NULL
between	NULL
SR-BP	NULL
and	NULL
Erg2p-SR-BP	NULL
shares	NULL
a	NULL
significant	NULL
sequence	NULL
identity	NULL
with	NULL
Erg2p	NULL
(	NULL
29.9	NULL
%	NULL
)	NULL
.	NULL

We	NULL
have	NULL
shown	NULL
that	NULL
this	NULL
latter	NULL
protein	NULL
is	NULL
the	NULL
target	NULL
that	NULL
mediates	NULL
the	NULL
anti-proliferation	NULL
effects	NULL
of	NULL
SR	NULL
31747A	NULL
in	NULL
yeast	NULL
(	NULL
23	NULL
)	NULL
.	NULL

Results	NULL
presented	NULL
here	NULL
as	NULL
well	NULL
as	NULL
those	NULL
of	NULL
Hanner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
show	NULL
that	NULL
yeast	NULL
Erg2p	NULL
and	NULL
mammalian	NULL
sigma	NULL
1	NULL
receptor	NULL
or	NULL
SR-BP	NULL
,	NULL
whether	NULL
of	NULL
guinea-pig	NULL
or	NULL
human	NULL
source	NULL
,	NULL
are	NULL
related	NULL
to	NULL
one	NULL
another	NULL
not	NULL
only	NULL
structurally	NULL
but	NULL
also	NULL
pharmacologically	NULL
.	NULL

In	NULL
fact	NULL
,	NULL
only	NULL
pentazocine	NULL
clearly	NULL
distinguishes	NULL
both	NULL
proteins	NULL
,	NULL
whereas	NULL
SR	NULL
31747A	NULL
,	NULL
haloperidol	NULL
,	NULL
ifenprodil	NULL
,	NULL
and	NULL
drugs	NULL
of	NULL
the	NULL
N-substituted	NULL
morpholine	NULL
derivative	NULL
family	NULL
,	NULL
like	NULL
tridemorph	NULL
and	NULL
fenpropimorph	NULL
,	NULL
all	NULL
bind	NULL
to	NULL
both	NULL
proteins	NULL
with	NULL
high	NULL
affinity	NULL
.	NULL

Tridemorph	NULL
and	NULL
fenpropimorph	NULL
are	NULL
known	NULL
to	NULL
inhibit	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
,	NULL
as	NULL
well	NULL
as	NULL
other	NULL
enzymes	NULL
of	NULL
the	NULL
sterol	NULL
biosyn-thetic	NULL
pathway	NULL
,	NULL
presumably	NULL
by	NULL
mimicking	NULL
the	NULL
high	NULL
energy	NULL
carbocationic	NULL
reaction	NULL
intermediate	NULL
(	NULL
38	NULL
)	NULL
.	NULL

These	NULL
drugs	NULL
can	NULL
therefore	NULL
be	NULL
considered	NULL
as	NULL
belonging	NULL
to	NULL
a	NULL
non-sterol	NULL
class	NULL
of	NULL
sterol	NULL
analogs	NULL
that	NULL
bind	NULL
to	NULL
the	NULL
reactive	NULL
sterol-binding	NULL
pocket	NULL
of	NULL
sterol	NULL
biosynthesis	NULL
enzymes	NULL
.	NULL

Sequence	NULL
alignment	NULL
of	NULL
the	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
from	NULL
S.	NULL
cerevisiae	NULL
(	NULL
34	NULL
)	NULL
,	NULL
the	NULL
rice	NULL
blast	NULL
fungus	NULL
M.	NULL
grisea	NULL
(	NULL
39	NULL
)	NULL
,	NULL
and	NULL
the	NULL
maize	NULL
smut	NULL
pathogen	NULL
U.	NULL
maydis	NULL
(	NULL
89	NULL
)	NULL
show	NULL
a	NULL
strikingly	NULL
high	NULL
percentage	NULL
of	NULL
similarity	NULL
within	NULL
the	NULL
central	NULL
hydrophobic	NULL
region	NULL
.	NULL

For	NULL
this	NULL
reason	NULL
,	NULL
this	NULL
central	NULL
domain	NULL
has	NULL
been	NULL
suggested	NULL
to	NULL
contain	NULL
the	NULL
sterol	NULL
isomerase	NULL
catalytic	NULL
site	NULL
.	NULL

Interestingly	NULL
,	NULL
SR-BP	NULL
,	NULL
which	NULL
displays	NULL
a	NULL
hydropathy	NULL
profile	NULL
similar	NULL
to	NULL
that	NULL
of	NULL
fungal	NULL
sterol	NULL
isomerase	NULL
,	NULL
also	NULL
presents	NULL
this	NULL
highly	NULL
conserved	NULL
central	NULL
domain	NULL
.	NULL

This	NULL
observation	NULL
raises	NULL
two	NULL
hypoth-eses	NULL
:	NULL
first	NULL
,	NULL
the	NULL
presumably	NULL
catalytic	NULL
domain	NULL
of	NULL
Erg2p	NULL
,	NULL
and	NULL
the	NULL
equivalent	NULL
central	NULL
hydrophobic	NULL
domain	NULL
of	NULL
SR-BP	NULL
might	NULL
contain	NULL
the	NULL
sigma	NULL
ligand	NULL
binding	NULL
site	NULL
.	NULL

This	NULL
could	NULL
be	NULL
illustrated	NULL
by	NULL
the	NULL
property	NULL
of	NULL
fenpropimorph	NULL
to	NULL
competitively	NULL
inhibit	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
and	NULL
other	NULL
sterol	NULL
biosynthesis	NULL
enzymes	NULL
(	NULL
23	NULL
,	NULL
38	NULL
)	NULL
.	NULL

The	NULL
second	NULL
hypothesis	NULL
is	NULL
that	NULL
SR-BP	NULL
may	NULL
exhibit	NULL
a	NULL
C8-C7	NULL
sterol	NULL
isomerase	NULL
activity	NULL
.	NULL

This	NULL
hypothesis	NULL
is	NULL
supported	NULL
by	NULL
the	NULL
high	NULL
affinity	NULL
of	NULL
the	NULL
sterol	NULL
isomerase	NULL
competitive	NULL
inhibitors	NULL
tridemorph	NULL
and	NULL
fenpropimorph	NULL
to	NULL
bind	NULL
to	NULL
SR-BP	NULL
.	NULL

However	NULL
,	NULL
it	NULL
is	NULL
not	NULL
supported	NULL
by	NULL
expression	NULL
studies	NULL
in	NULL
yeast	NULL
,	NULL
since	NULL
no	NULL
complementation	NULL
of	NULL
any	NULL
of	NULL
the	NULL
Erg2p	NULL
defect	NULL
,	NULL
i.e	NULL
.	NULL

CS-sterol	NULL
accumulation	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
and	NULL
ergosterol	NULL
prototrophy	NULL
,	NULL
was	NULL
observed	NULL
by	NULL
expressing	NULL
either	NULL
the	NULL
guinea-pig	NULL
sigma	NULL
1	NULL
receptor	NULL
(	NULL
32	NULL
)	NULL
or	NULL
the	NULL
human	NULL
SR-BP	NULL
in	NULL
an	NULL
ERG2	NULL
gene	NULL
disruptant	NULL
(	NULL
this	NULL
study	NULL
)	NULL
.	NULL

No	NULL
ergosterol	NULL
could	NULL
be	NULL
detected	NULL
in	NULL
pEMR1499-transformed	NULL
EMY47	NULL
cells	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

We	NULL
can	NULL
not	NULL
exclude	NULL
that	NULL
recombinant	NULL
SR-BP	NULL
produced	NULL
in	NULL
yeast	NULL
is	NULL
synthesized	NULL
in	NULL
an	NULL
active	NULL
form	NULL
but	NULL
localized	NULL
in	NULL
subcellular	NULL
compartments	NULL
where	NULL
sterol	NULL
biosynthesis	NULL
does	NULL
not	NULL
take	NULL
place	NULL
,	NULL
as	NULL
has	NULL
been	NULL
suggested	NULL
in	NULL
the	NULL
case	NULL
of	NULL
recombinant	NULL
human	NULL
squalene	NULL
synthase	NULL
(	NULL
40	NULL
)	NULL
.	NULL

Alternatively	NULL
,	NULL
the	NULL
enzymatically	NULL
active	NULL
form	NULL
of	NULL
SR-BP	NULL
might	NULL
require	NULL
specific	NULL
post-translation	NULL
modification	NULL
events	NULL
that	NULL
do	NULL
not	NULL
occur	NULL
in	NULL
yeast	NULL
cells	NULL
.	NULL

Finally	NULL
,	NULL
one	NULL
should	NULL
not	NULL
exclude	NULL
that	NULL
SR-BP	NULL
function	NULL
(	NULL
s	NULL
)	NULL
might	NULL
not	NULL
include	NULL
the	NULL
sterol	NULL
isomerization	NULL
reaction	NULL
as	NULL
performed	NULL
by	NULL
Erg2p	NULL
in	NULL
yeast	NULL
.	NULL

It	NULL
is	NULL
worth	NULL
noting	NULL
that	NULL
we	NULL
have	NULL
already	NULL
cloned	NULL
a	NULL
mammalian	NULL
enzyme	NULL
by	NULL
complementation	NULL
of	NULL
the	NULL
Erg2p	NULL
defect	NULL
in	NULL
yeast	NULL
(	NULL
38	NULL
)	NULL
.	NULL

This	NULL
microsomal	NULL
protein	NULL
displays	NULL
all	NULL
the	NULL
biochemical	NULL
characteristics	NULL
expected	NULL
for	NULL
mammalian	NULL
sterol	NULL
isomerase	NULL
,	NULL
including	NULL
sensitivity	NULL
to	NULL
drugs	NULL
that	NULL
specifically	NULL
inhibit	NULL
the	NULL
activity	NULL
of	NULL
this	NULL
enzyme	NULL
in	NULL
mammals	NULL
(	NULL
38	NULL
)	NULL
.	NULL

Surprisingly	NULL
,	NULL
this	NULL
enzyme	NULL
is	NULL
absolutely	NULL
not	NULL
related	NULL
phylogenetically	NULL
to	NULL
Erg2p	NULL
or	NULL
SR-BP	NULL
;	NULL
it	NULL
does	NULL
not	NULL
share	NULL
any	NULL
striking	NULL
structural	NULL
similarity	NULL
with	NULL
any	NULL
members	NULL
of	NULL
the	NULL
Erg2p	NULL
family	NULL
including	NULL
SR-BP	NULL
.	NULL

However	NULL
,	NULL
mammalian	NULL
sterol	NULL
isomerase	NULL
does	NULL
contain	NULL
a	NULL
sigma	NULL
ligand	NULL
binding	NULL
site	NULL
(	NULL
32	NULL
,	NULL
38	NULL
)	NULL
.	NULL

This	NULL
observation	NULL
supports	NULL
the	NULL
hypothesis	NULL
that	NULL
the	NULL
sterol-binding	NULL
pocket	NULL
present	NULL
in	NULL
sterol	NULL
isomerase	NULL
,	NULL
whether	NULL
belonging	NULL
to	NULL
the	NULL
Erg2p	NULL
family	NULL
or	NULL
not	NULL
,	NULL
indeed	NULL
constitutes	NULL
the	NULL
sigma	NULL
ligand	NULL
binding	NULL
site	NULL
.	NULL

It	NULL
also	NULL
suggests	NULL
that	NULL
other	NULL
sterol	NULL
metabolism	NULL
enzymes	NULL
might	NULL
present	NULL
sigma	NULL
ligand	NULL
binding	NULL
sites	NULL
as	NULL
well	NULL
.	NULL

Distribution	NULL
and	NULL
Subcellular	NULL
Localization	NULL
of	NULL
SR-BP-The	NULL
tissular	NULL
distribution	NULL
of	NULL
human	NULL
SR-BP	NULL
mRNA	NULL
revealed	NULL
a	NULL
major	NULL
transcript	NULL
of	NULL
2	NULL
kilobases	NULL
,	NULL
which	NULL
was	NULL
found	NULL
to	NULL
be	NULL
ubiquitous	NULL
,	NULL
although	NULL
its	NULL
abundance	NULL
varied	NULL
among	NULL
tissues	NULL
.	NULL

The	NULL
transcript	NULL
was	NULL
most	NULL
abundant	NULL
in	NULL
the	NULL
liver	NULL
,	NULL
and	NULL
lower	NULL
in	NULL
brain	NULL
.	NULL

This	NULL
latter	NULL
observation	NULL
clearly	NULL
contrasts	NULL
with	NULL
the	NULL
high	NULL
expression	NULL
level	NULL
of	NULL
sigma	NULL
1	NULL
receptor	NULL
mRNA	NULL
in	NULL
brain	NULL
guinea	NULL
pig	NULL
reported	NULL
by	NULL
Hanner	NULL
et	NULL
al	NULL
.	NULL

(	NULL
32	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
a	NULL
major	NULL
difference	NULL
in	NULL
tissue	NULL
expression	NULL
of	NULL
sigma	NULL
1	NULL
receptor	NULL
or	NULL
SR-BP	NULL
in	NULL
guinea	NULL
pig	NULL
and	NULL
human	NULL
.	NULL

Further	NULL
investigations	NULL
using	NULL
specific	NULL
anti-SR-BP	NULL
antibodies	NULL
are	NULL
required	NULL
to	NULL
document	NULL
this	NULL
in	NULL
particular	NULL
to	NULL
interpret	NULL
the	NULL
neurological	NULL
activities	NULL
of	NULL
sigma	NULL
ligands	NULL
in	NULL
rodent	NULL
and	NULL
human	NULL
.	NULL

In	NULL
cells	NULL
expressing	NULL
SR-BP	NULL
,	NULL
the	NULL
subcellular	NULL
localization	NULL
using	NULL
specific	NULL
monoclonal	NULL
antibodies	NULL
showed	NULL
that	NULL
SR-BP	NULL
is	NULL
always	NULL
associated	NULL
with	NULL
the	NULL
nuclear	NULL
envelope	NULL
,	NULL
strongly	NULL
suggesting	NULL
that	NULL
SR-BP	NULL
is	NULL
an	NULL
ubiquitous	NULL
component	NULL
of	NULL
the	NULL
nuclear	NULL
membrane	NULL
.	NULL

We	NULL
also	NULL
observed	NULL
that	NULL
,	NULL
when	NULL
the	NULL
nuclear	NULL
envelope	NULL
disassembles	NULL
at	NULL
the	NULL
onset	NULL
of	NULL
mitosis	NULL
and	NULL
reassembles	NULL
at	NULL
the	NULL
end	NULL
of	NULL
mitosis	NULL
,	NULL
the	NULL
SR-BP	NULL
follows	NULL
the	NULL
same	NULL
dynamics	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

Our	NULL
finding	NULL
of	NULL
a	NULL
subcellular	NULL
localization	NULL
of	NULL
SR-BP	NULL
in	NULL
nuclear	NULL
membrane	NULL
was	NULL
substantiated	NULL
by	NULL
the	NULL
presence	NULL
of	NULL
a	NULL
hydrophobic	NULL
domain	NULL
near	NULL
the	NULL
N	NULL
terminus	NULL
.	NULL

The	NULL
cytosolic	NULL
localization	NULL
,	NULL
which	NULL
was	NULL
also	NULL
observed	NULL
,	NULL
was	NULL
different	NULL
from	NULL
one	NULL
cell	NULL
line	NULL
to	NULL
another	NULL
and	NULL
remains	NULL
to	NULL
be	NULL
further	NULL
explored	NULL
.	NULL

Within	NULL
the	NULL
nuclear	NULL
mem-brane	NULL
,	NULL
the	NULL
lack	NULL
of	NULL
recognition	NULL
of	NULL
SR-BP	NULL
by	NULL
mAbs	NULL
applied	NULL
to	NULL
intact	NULL
isolated	NULL
nuclei	NULL
indicates	NULL
that	NULL
the	NULL
epitope	NULL
recognized	NULL
by	NULL
the	NULL
mAb	NULL
is	NULL
not	NULL
exposed	NULL
to	NULL
the	NULL
cytoplasm	NULL
.	NULL

However	NULL
,	NULL
further	NULL
investigations	NULL
are	NULL
required	NULL
to	NULL
determine	NULL
whether	NULL
SR-BP	NULL
belongs	NULL
to	NULL
the	NULL
inner	NULL
or	NULL
outer	NULL
nuclear	NULL
membrane	NULL
.	NULL

Biological	NULL
Effect	NULL
of	NULL
SR	NULL
31747A	NULL
and	NULL
SR-BP-We	NULL
have	NULL
shown	NULL
previously	NULL
that	NULL
SR	NULL
31747A	NULL
blocks	NULL
T	NULL
lymphocyte	NULL
proliferation	NULL
.	NULL

Several	NULL
findings	NULL
from	NULL
this	NULL
study	NULL
support	NULL
the	NULL
possibility	NULL
that	NULL
SR	NULL
31747A	NULL
effects	NULL
are	NULL
mediated	NULL
by	NULL
SR-BP	NULL
.	NULL

1	NULL
)	NULL
We	NULL
showed	NULL
the	NULL
presence	NULL
of	NULL
SR-BP	NULL
in	NULL
immune	NULL
tissue	NULL
at	NULL
the	NULL
mRNA	NULL
level	NULL
.	NULL

The	NULL
expression	NULL
of	NULL
the	NULL
protein	NULL
in	NULL
purified	NULL
T	NULL
cells	NULL
as	NULL
well	NULL
as	NULL
in	NULL
macrophages	NULL
was	NULL
also	NULL
demonstrated	NULL
by	NULL
flow	NULL
cytometry	NULL
using	NULL
an	NULL
anti-SR-BP	NULL
antibody	NULL
(	NULL
data	NULL
not	NULL
shown	NULL
)	NULL
.	NULL

These	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
results	NULL
are	NULL
in	NULL
agreement	NULL
with	NULL
recent	NULL
studies	NULL
from	NULL
Wolfe	NULL
et	NULL
al	NULL
.	NULL

(	NULL
22	NULL
)	NULL
,	NULL
who	NULL
showed	NULL
,	NULL
using	NULL
in	NULL
vitro	NULL
receptor	NULL
autoradiography	NULL
in	NULL
frozen	NULL
sections	NULL
of	NULL
rat	NULL
spleen	NULL
,	NULL
that	NULL
sigma	NULL
1	NULL
receptors	NULL
were	NULL
present	NULL
throughout	NULL
the	NULL
spleen	NULL
and	NULL
particularly	NULL
concentrated	NULL
in	NULL
the	NULL
T	NULL
cell	NULL
zones	NULL
.	NULL

2	NULL
)	NULL
We	NULL
demonstrated	NULL
that	NULL
the	NULL
effect	NULL
of	NULL
SR	NULL
31747	NULL
on	NULL
T	NULL
cell	NULL
proliferation	NULL
was	NULL
blocked	NULL
by	NULL
the	NULL
competitive	NULL
ligand	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

This	NULL
finding	NULL
is	NULL
consistent	NULL
with	NULL
a	NULL
sigma	NULL
1	NULL
receptor-mediated	NULL
event	NULL
.	NULL

Although	NULL
the	NULL
clear	NULL
definition	NULL
of	NULL
agonist	NULL
and	NULL
antagonist	NULL
at	NULL
the	NULL
sigma	NULL
1	NULL
receptor	NULL
is	NULL
difficult	NULL
,	NULL
these	NULL
results	NULL
suggest	NULL
that	NULL
SR	NULL
31747A	NULL
and	NULL
pentazocine	NULL
display	NULL
opposite	NULL
biological	NULL
effects	NULL
.	NULL

We	NULL
have	NULL
already	NULL
established	NULL
that	NULL
SR	NULL
31747	NULL
affects	NULL
a	NULL
late	NULL
event	NULL
in	NULL
the	NULL
activation	NULL
process	NULL
of	NULL
T	NULL
lymphocytes	NULL
which	NULL
occurs	NULL
during	NULL
the	NULL
S/G	NULL
;	NULL
y/M	NULL
phases	NULL
of	NULL
the	NULL
cell	NULL
cycle	NULL
(	NULL
14	NULL
)	NULL
.	NULL

This	NULL
suggests	NULL
that	NULL
the	NULL
function	NULL
of	NULL
SR-BP	NULL
could	NULL
be	NULL
essential	NULL
for	NULL
T	NULL
lymphocyte	NULL
mitogenesis	NULL
.	NULL

Furthermore	NULL
,	NULL
and	NULL
taking	NULL
into	NULL
account	NULL
(	NULL
i	NULL
)	NULL
the	NULL
nuclear	NULL
membrane	NULL
localization	NULL
of	NULL
SR-BP	NULL
,	NULL
(	NULL
ii	NULL
)	NULL
the	NULL
dramatic	NULL
changes	NULL
in	NULL
nuclear	NULL
membrane	NULL
during	NULL
mitosis	NULL
,	NULL
(	NULL
iii	NULL
)	NULL
the	NULL
homology	NULL
of	NULL
SR-BP	NULL
with	NULL
sterol	NULL
isomerase	NULL
,	NULL
and	NULL
(	NULL
iv	NULL
)	NULL
the	NULL
known	NULL
effects	NULL
of	NULL
cholesterol	NULL
on	NULL
the	NULL
activity	NULL
of	NULL
membrane	NULL
proteins	NULL
,	NULL
one	NULL
may	NULL
speculate	NULL
that	NULL
some	NULL
of	NULL
the	NULL
effects	NULL
of	NULL
SR	NULL
31747¥	NULL
on	NULL
T	NULL
cell	NULL
mitogenesis	NULL
could	NULL
be	NULL
mediated	NULL
by	NULL
changes	NULL
in	NULL
membrane	NULL
lipids	NULL
.	NULL

Even	NULL
though	NULL
our	NULL
study	NULL
does	NULL
not	NULL
definitively	NULL
prove	NULL
that	NULL
SR-BP	NULL
is	NULL
the	NULL
site	NULL
through	NULL
which	NULL
SR	NULL
31747A	NULL
modulates	NULL
immune	NULL
functions	NULL
,	NULL
we	NULL
can	NULL
not	NULL
rule	NULL
out	NULL
that	NULL
SR	NULL
31747A	NULL
could	NULL
be	NULL
effective	NULL
through	NULL
other	NULL
sites	NULL
not	NULL
yet	NULL
identified	NULL
.	NULL

An	NULL
accurate	NULL
structure-activity	NULL
relationship	NULL
study	NULL
should	NULL
help	NULL
to	NULL
elucidate	NULL
such	NULL
an	NULL
important	NULL
question	NULL
.	NULL

In	NULL
conclusion	NULL
,	NULL
we	NULL
have	NULL
identified	NULL
and	NULL
characterized	NULL
a	NULL
high	NULL
affinity	NULL
binding	NULL
protein	NULL
for	NULL
SR	NULL
31747	NULL
and	NULL
shown	NULL
that	NULL
this	NULL
protein	NULL
is	NULL
the	NULL
human	NULL
sigma	NULL
1	NULL
receptor	NULL
.	NULL

We	NULL
also	NULL
demonstrated	NULL
that	NULL
both	NULL
binding	NULL
and	NULL
activity	NULL
of	NULL
SR	NULL
31747	NULL
could	NULL
be	NULL
reversed	NULL
by	NULL
(	NULL
+	NULL
)	NULL
-pentazocine	NULL
.	NULL

This	NULL
important	NULL
property	NULL
strongly	NULL
suggests	NULL
that	NULL
the	NULL
sigma	NULL
1	NULL
receptor	NULL
displays	NULL
biological	NULL
functions	NULL
and	NULL
provides	NULL
new	NULL
tools	NULL
for	NULL
further	NULL
mechanistic	NULL
investigations	NULL
.	NULL

Acknowledgments-We	NULL
thank	NULL
Dr.	NULL
Nadir	NULL
Mechti	NULL
(	NULL
Institut	NULL
de	NULL
Génét-ique	NULL
Moléculaire	NULL
,	NULL
Montpellier	NULL
,	NULL
France	NULL
)	NULL
for	NULL
the	NULL
gracious	NULL
gift	NULL
of	NULL
Daudi	NULL
A	NULL
UniZAP	NULL
XR	NULL
cDNA	NULL
library	NULL
and	NULL
Prof.	NULL
Dr.	NULL
Gerhard	NULL
GroB	NULL
(	NULL
Knoll	NULL
AG	NULL
,	NULL
Ludwigshafen	NULL
,	NULL
Germany	NULL
)	NULL
for	NULL
kindly	NULL
providing	NULL
us	NULL
with	NULL
emopamil	NULL
.	NULL

REFERENCES	NULL
1	NULL
.	NULL

Martin	NULL
,	NULL
W.	NULL
R.	NULL
,	NULL
Eades	NULL
,	NULL
C.	NULL
G.	NULL
,	NULL
Thomson	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Hoppler	NULL
,	NULL
R.	NULL
E.	NULL
,	NULL
and	NULL
Gilbert	NULL
,	NULL
P.	NULL
E.	NULL
(	NULL
1976	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

197	NULL
,	NULL
517-532	NULL
.	NULL

Su	NULL
,	NULL
T.-P.	NULL
(	NULL
1981	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

75	NULL
,	NULL
81-82	NULL
.	NULL

Su	NULL
,	NULL
T.-P.	NULL
(	NULL
1982	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

228	NULL
,	NULL
284-290	NULL
.	NULL

Gundlack	NULL
,	NULL
A.	NULL
L.	NULL
,	NULL
Largent	NULL
,	NULL
B.	NULL
L.	NULL
,	NULL
and	NULL
Snyder	NULL
,	NULL
S.	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Newrosci	NULL
.	NULL

6	NULL
,	NULL
1757-1770	NULL
5	NULL
.	NULL

Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
Culp	NULL
,	NULL
S.	NULL
G.	NULL
,	NULL
and	NULL
De	NULL
Souza	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Endocrinology	NULL
124	NULL
,	NULL
1160-1172	NULL
6	NULL
.	NULL

Roman	NULL
,	NULL
F.	NULL
J.	NULL
,	NULL
Pascaud	NULL
,	NULL
X.	NULL
,	NULL
Chomette	NULL
,	NULL
G.	NULL
,	NULL
Buéno	NULL
,	NULL
L.	NULL
,	NULL
and	NULL
Junien	NULL
,	NULL
J.	NULL
L.	NULL
(	NULL
1989	NULL
)	NULL
Gastroenterology	NULL
97	NULL
,	NULL
T6	NULL
7	NULL
.	NULL

Samovilova	NULL
,	NULL
N.	NULL
N.	NULL
,	NULL
Nagornaya	NULL
,	NULL
L.	NULL
V.	NULL
,	NULL
and	NULL
Vinogradov	NULL
,	NULL
V.	NULL
A	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

147	NULL
,	NULL
259-264	NULL
8	NULL
.	NULL

Hellewell	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
Bruce	NULL
,	NULL
A.	NULL
,	NULL
Feinstein	NULL
,	NULL
G.	NULL
,	NULL
Orringer	NULL
,	NULL
J.	NULL
,	NULL
Williams	NULL
,	NULL
W.	NULL
,	NULL
and	NULL
im	NULL
Co	NULL
bo	NULL
27115	NULL
Bowen	NULL
,	NULL
W.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

268	NULL
,	NULL
9-18	NULL
9	NULL
.	NULL

Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
Kulsakdinun	NULL
,	NULL
C.	NULL
,	NULL
Battaglia	NULL
,	NULL
G.	NULL
,	NULL
Jaffe	NULL
,	NULL
J.	NULL
H.	NULL
,	NULL
and	NULL
De	NULL
Souza	NULL
,	NULL
10	NULL
.	NULL

11	NULL
.	NULL

12	NULL
.	NULL

13	NULL
.	NULL

14	NULL
.	NULL

15	NULL
.	NULL

16	NULL
.	NULL

17	NULL
.	NULL

18	NULL
.	NULL

19	NULL
.	NULL

20	NULL
.	NULL

21	NULL
.	NULL

22	NULL
.	NULL

28	NULL
.	NULL

24	NULL
.	NULL

25	NULL
.	NULL

26.	NULL
.	NULL

Laemmli	NULL
,	NULL
U.	NULL
K.	NULL
(	NULL
1970	NULL
)	NULL
Nature	NULL
227	NULL
,	NULL
680-685	NULL
28	NULL
.	NULL

29	NULL
.	NULL

30	NULL
.	NULL

31	NULL
.	NULL

82	NULL
.	NULL

33	NULL
.	NULL

34	NULL
.	NULL

35	NULL
.	NULL

36	NULL
.	NULL

37	NULL
.	NULL

38	NULL
.	NULL

39	NULL
.	NULL

40	NULL
.	NULL

41	NULL
.	NULL

E.	NULL
B	NULL
.	NULL

(	NULL
1988	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

247	NULL
,	NULL
1114-1119	NULL
Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
De	NULL
Souza	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1992	NULL
)	NULL
in	NULL
Multiple	NULL
Sigma	NULL
and	NULL
PCP	NULL
Receptor	NULL
Ligands	NULL
:	NULL
Mechanisms	NULL
for	NULL
Neuro-modulation	NULL
and	NULL
Neuroprotection	NULL
?	NULL

(	NULL
Kamenka	NULL
,	NULL
J.	NULL
M.	NULL
,	NULL
and	NULL
Domino	NULL
,	NULL
E.	NULL
F.	NULL
,	NULL
eds	NULL
)	NULL
pp	NULL
.	NULL

927-958	NULL
,	NULL
NPP	NULL
Books	NULL
,	NULL
Ann	NULL
Arbor	NULL
,	NULL
MI	NULL
Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
and	NULL
De	NULL
Souza	NULL
,	NULL
E.	NULL
B	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
in	NULL
Sigma	NULL
Receptors	NULL
(	NULL
Itzhak	NULL
,	NULL
Y.	NULL
,	NULL
ed	NULL
)	NULL
pp	NULL
.	NULL

287-317	NULL
,	NULL
Academic	NULL
Press	NULL
Inc.	NULL
,	NULL
San	NULL
Diego	NULL
Liu	NULL
,	NULL
Y.	NULL
,	NULL
Whitlock	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Pultz	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
and	NULL
Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Neuroimmunol	NULL
.	NULL

59	NULL
,	NULL
148-154	NULL
Paul	NULL
,	NULL
R.	NULL
,	NULL
Lavastre	NULL
,	NULL
S.	NULL
,	NULL
Floutard	NULL
,	NULL
D.	NULL
,	NULL
Floutard	NULL
,	NULL
R.	NULL
,	NULL
Canat	NULL
,	NULL
X.	NULL
,	NULL
Casellas	NULL
,	NULL
P.	NULL
,	NULL
Le	NULL
Fur	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Breligre	NULL
,	NULL
J.-C.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Nevroimmunol	NULL
.	NULL

52	NULL
,	NULL
188-192	NULL
Casellas	NULL
,	NULL
P.	NULL
,	NULL
Bourrié	NULL
,	NULL
B.	NULL
,	NULL
Canat	NULL
,	NULL
X.	NULL
,	NULL
Carayon	NULL
,	NULL
P.	NULL
,	NULL
Buisson	NULL
,	NULL
I.	NULL
,	NULL
Paul	NULL
,	NULL
R.	NULL
,	NULL
Breli¢re	NULL
,	NULL
J.-C.	NULL
,	NULL
and	NULL
Le	NULL
Fur	NULL
,	NULL
G.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Neuroimmunol	NULL
.	NULL

52	NULL
,	NULL
193-203	NULL
Bowen	NULL
,	NULL
W.	NULL
D.	NULL
,	NULL
Hellewell	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
and	NULL
McGarry	NULL
,	NULL
K.	NULL
A	NULL
.	NULL

(	NULL
1989	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

163	NULL
,	NULL
309-318	NULL
Hellewell	NULL
,	NULL
S.	NULL
B.	NULL
,	NULL
and	NULL
Bowen	NULL
,	NULL
W.	NULL
D.	NULL
(	NULL
1990	NULL
)	NULL
Brain	NULL
Res	NULL
.	NULL

527	NULL
,	NULL
244-2583	NULL
Karbon	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
Naper	NULL
,	NULL
K.	NULL
,	NULL
and	NULL
Pontecorvo	NULL
,	NULL
M.	NULL
J	NULL
.	NULL

(	NULL
1991	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Pharmacol	NULL
.	NULL

198	NULL
,	NULL
21-27	NULL
Rothman	NULL
,	NULL
R.	NULL
B.	NULL
,	NULL
Reid	NULL
,	NULL
A.	NULL
,	NULL
Mahboubi	NULL
,	NULL
A.	NULL
,	NULL
Kim	NULL
,	NULL
C.-H.	NULL
,	NULL
de	NULL
Costa	NULL
,	NULL
B.	NULL
R.	NULL
,	NULL
Jacobson	NULL
,	NULL
A.	NULL
E.	NULL
,	NULL
and	NULL
Rice	NULL
,	NULL
K.	NULL
C.	NULL
(	NULL
1991	NULL
)	NULL
Mol	NULL
.	NULL

Pharmacol	NULL
.	NULL

89	NULL
,	NULL
222-232	NULL
Wu	NULL
,	NULL
X.-Z	NULL
.	NULL

,	NULL
Bell	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Spivak	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
London	NULL
,	NULL
E.	NULL
D.	NULL
,	NULL
and	NULL
Su	NULL
,	NULL
T.-P.	NULL
(	NULL
1991	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

257	NULL
,	NULL
351-859	NULL
Myers	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Charifson	NULL
,	NULL
P.	NULL
S.	NULL
,	NULL
Owens	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Kula	NULL
,	NULL
N.	NULL
S.	NULL
,	NULL
McPhail	NULL
,	NULL
A.	NULL
T.	NULL
,	NULL
Baldessarini	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Booth	NULL
,	NULL
R.	NULL
G.	NULL
,	NULL
and	NULL
Wyrick	NULL
,	NULL
S.	NULL
D.	NULL
(	NULL
1994	NULL
)	NULL
J.	NULL
Med	NULL
.	NULL

Chem	NULL
.	NULL

87	NULL
,	NULL
4109-4117	NULL
Whitlock	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
Liu	NULL
,	NULL
Y.	NULL
,	NULL
Chang	NULL
,	NULL
S.	NULL
,	NULL
Saini	NULL
,	NULL
P.	NULL
,	NULL
Ha	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
Barrett	NULL
,	NULL
T.	NULL
W.	NULL
,	NULL
and	NULL
Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Neuroimmunol	NULL
.	NULL

67	NULL
,	NULL
83-96	NULL
Wolfe	NULL
,	NULL
S.	NULL
A.	NULL
,	NULL
Jr.	NULL
,	NULL
Ha	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
Whitlock	NULL
,	NULL
B	NULL
.	NULL

B.	NULL
,	NULL
and	NULL
Saini	NULL
,	NULL
P.	NULL
(	NULL
1997	NULL
)	NULL
J.	NULL
Neurcimmunol	NULL
.	NULL

72	NULL
,	NULL
45-58	NULL
Silve	NULL
,	NULL
S.	NULL
,	NULL
Leplatois	NULL
,	NULL
P.	NULL
,	NULL
Josse	NULL
,	NULL
A.	NULL
,	NULL
Dupuy	NULL
,	NULL
P.-H.	NULL
,	NULL
Lanau	NULL
,	NULL
C.	NULL
,	NULL
Kaghad	NULL
,	NULL
M.	NULL
,	NULL
Dhers	NULL
,	NULL
C.	NULL
,	NULL
Picard	NULL
,	NULL
C.	NULL
,	NULL
Rahier	NULL
,	NULL
A.	NULL
,	NULL
Taton	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Fur	NULL
,	NULL
G.	NULL
,	NULL
Caput	NULL
,	NULL
D.	NULL
,	NULL
Ferrara	NULL
,	NULL
P.	NULL
,	NULL
and	NULL
Loison	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

16	NULL
,	NULL
2719-2727	NULL
Heinemeyer	NULL
,	NULL
W.	NULL
,	NULL
Kleinschmidt	NULL
,	NULL
J	NULL
.	NULL

A.	NULL
,	NULL
Saidowski	NULL
,	NULL
J.	NULL
,	NULL
Escher	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Wolf	NULL
,	NULL
D.	NULL
H.	NULL
(	NULL
1991	NULL
)	NULL
EMBO	NULL
J	NULL
.	NULL

10	NULL
,	NULL
555-562	NULL
Guthrie	NULL
,	NULL
C.	NULL
,	NULL
and	NULL
Fink	NULL
,	NULL
G.	NULL
R.	NULL
(	NULL
1991	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

194	NULL
,	NULL
1-863	NULL
Yaffe	NULL
,	NULL
M.	NULL
P.	NULL
(	NULL
1991	NULL
)	NULL
Methods	NULL
Enzymol	NULL
.	NULL

194	NULL
,	NULL
627-648	NULL
Hewick	NULL
,	NULL
R.	NULL
M.	NULL
,	NULL
Hunkapiller	NULL
,	NULL
M.	NULL
W.	NULL
,	NULL
Hood	NULL
,	NULL
L.	NULL
E.	NULL
,	NULL
and	NULL
Dreyer	NULL
,	NULL
W.	NULL
J	NULL
.	NULL

(	NULL
1981	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

256	NULL
,	NULL
7990-7997	NULL
Altschul	NULL
,	NULL
S.	NULL
P.	NULL
,	NULL
Gish	NULL
,	NULL
W.	NULL
,	NULL
Miller	NULL
,	NULL
W.	NULL
,	NULL
Myers	NULL
,	NULL
E.	NULL
W.	NULL
,	NULL
and	NULL
Lipman	NULL
,	NULL
D.	NULL
J	NULL
.	NULL

(	NULL
1990	NULL
)	NULL
J.	NULL
Mol	NULL
.	NULL

Biol	NULL
.	NULL

215	NULL
,	NULL
408-410	NULL
Church	NULL
,	NULL
G.	NULL
M.	NULL
,	NULL
and	NULL
Gilbert	NULL
,	NULL
W.	NULL
(	NULL
1984	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

81	NULL
,	NULL
1991-1995	NULL
Dussossoy	NULL
,	NULL
D.	NULL
,	NULL
Carayon	NULL
,	NULL
P.	NULL
,	NULL
Feraut	NULL
,	NULL
D.	NULL
,	NULL
Belugou	NULL
,	NULL
S.	NULL
,	NULL
Combes	NULL
,	NULL
T.	NULL
,	NULL
Canat	NULL
,	NULL
X.	NULL
,	NULL
Vidal	NULL
,	NULL
H.	NULL
,	NULL
and	NULL
Casellas	NULL
,	NULL
P.	NULL
(	NULL
1996	NULL
)	NULL
Cytometry	NULL
24	NULL
,	NULL
39-48	NULL
Hanner	NULL
,	NULL
M.	NULL
,	NULL
Moebius	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
Flandorfer	NULL
,	NULL
A.	NULL
,	NULL
Knaus	NULL
,	NULL
H.-G.	NULL
,	NULL
Striessnig	NULL
,	NULL
J.	NULL
,	NULL
Kempner	NULL
,	NULL
E.	NULL
,	NULL
and	NULL
Glossmann	NULL
,	NULL
H.	NULL
(	NULL
1996	NULL
)	NULL
Proc	NULL
.	NULL

Natl	NULL
.	NULL

Acad	NULL
.	NULL

Sci	NULL
.	NULL

U.	NULL
S.	NULL
A	NULL
.	NULL

98	NULL
,	NULL
8072-8077	NULL
Kekuda	NULL
,	NULL
R.	NULL
,	NULL
Prasad	NULL
,	NULL
P.	NULL
D.	NULL
,	NULL
Fei	NULL
,	NULL
Y.	NULL
J.	NULL
,	NULL
Leibach	NULL
,	NULL
F.	NULL
H.	NULL
,	NULL
and	NULL
Ganapathy	NULL
,	NULL
V.	NULL
(	NULL
1996	NULL
)	NULL
Biochem	NULL
.	NULL

Biophys	NULL
.	NULL

Res	NULL
.	NULL

Commun	NULL
.	NULL

229	NULL
,	NULL
553-558	NULL
Ashman	NULL
,	NULL
W.	NULL
H.	NULL
,	NULL
Barbuch	NULL
,	NULL
R.	NULL
J.	NULL
,	NULL
Ulbright	NULL
,	NULL
C.	NULL
E.	NULL
,	NULL
Jarrett	NULL
,	NULL
H.	NULL
W.	NULL
,	NULL
and	NULL
Bard	NULL
,	NULL
M.	NULL
(	NULL
1991	NULL
)	NULL
Lipids	NULL
26	NULL
,	NULL
628-632	NULL
Derocq	NULL
,	NULL
J.-M.	NULL
,	NULL
Bourrié	NULL
,	NULL
B.	NULL
,	NULL
Ségui	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Fur	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Casellas	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
J.	NULL
Pharmacol	NULL
.	NULL

Exp	NULL
.	NULL

Ther	NULL
.	NULL

272	NULL
,	NULL
224-230	NULL
Bourrié	NULL
,	NULL
B.	NULL
,	NULL
Bouaboula	NULL
,	NULL
M.	NULL
,	NULL
Benoit	NULL
,	NULL
J.-M.	NULL
,	NULL
Derocq	NULL
,	NULL
J.-M.	NULL
,	NULL
Esclangon	NULL
,	NULL
M.	NULL
,	NULL
Le	NULL
Fur	NULL
,	NULL
G.	NULL
,	NULL
and	NULL
Casellas	NULL
,	NULL
P.	NULL
(	NULL
1995	NULL
)	NULL
Eur	NULL
.	NULL

J.	NULL
Immunol	NULL
.	NULL

25	NULL
,	NULL
2882-2887	NULL
Moebius	NULL
,	NULL
F.	NULL
F.	NULL
,	NULL
Striessnig	NULL
,	NULL
J.	NULL
,	NULL
and	NULL
Glossmann	NULL
,	NULL
H.	NULL
(	NULL
1997	NULL
)	NULL
Trends	NULL
Pharmacol	NULL
.	NULL

Sci	NULL
.	NULL

18	NULL
,	NULL
67-70	NULL
Silve	NULL
,	NULL
S.	NULL
,	NULL
Dupuy	NULL
,	NULL
P.	NULL
H.	NULL
,	NULL
Labit-Lebouteiller	NULL
,	NULL
C.	NULL
,	NULL
Kaghad	NULL
,	NULL
M.	NULL
,	NULL
Chalon	NULL
,	NULL
P.	NULL
,	NULL
Rahier	NULL
,	NULL
A.	NULL
,	NULL
Taton	NULL
,	NULL
M.	NULL
,	NULL
Lupker	NULL
,	NULL
J.	NULL
,	NULL
Shire	NULL
,	NULL
D.	NULL
,	NULL
and	NULL
Loison	NULL
,	NULL
G.	NULL
(	NULL
1996	NULL
)	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

271	NULL
,	NULL
22434-22440	NULL
Keon	NULL
,	NULL
J.	NULL
P.	NULL
R.	NULL
,	NULL
James	NULL
,	NULL
C.	NULL
S.	NULL
,	NULL
Court	NULL
,	NULL
S.	NULL
,	NULL
Baden-Daintree	NULL
,	NULL
C.	NULL
,	NULL
Bailey	NULL
,	NULL
A.	NULL
M.	NULL
,	NULL
Burden	NULL
,	NULL
R.	NULL
S.	NULL
,	NULL
Bard	NULL
,	NULL
M.	NULL
,	NULL
and	NULL
Hargreaves	NULL
,	NULL
J	NULL
.	NULL

A	NULL
.	NULL

(	NULL
1994	NULL
)	NULL
Curr	NULL
.	NULL

Genet	NULL
.	NULL

25	NULL
,	NULL
531-537	NULL
Robinson	NULL
,	NULL
G.	NULL
W.	NULL
,	NULL
Tsay	NULL
,	NULL
E.	NULL
Y.	NULL
,	NULL
Kienzle	NULL
,	NULL
B.	NULL
K.	NULL
,	NULL
Smith-Monroy	NULL
,	NULL
C.	NULL
A.	NULL
,	NULL
and	NULL
Bishop	NULL
,	NULL
R.	NULL
W.	NULL
(	NULL
1993	NULL
)	NULL
Mol	NULL
.	NULL

Cell	NULL
.	NULL

Biol	NULL
.	NULL

18	NULL
,	NULL
2706-2717	NULL
De	NULL
Lean	NULL
,	NULL
A.	NULL
,	NULL
Munson	NULL
,	NULL
P.	NULL
J.	NULL
,	NULL
and	NULL
Rodbard	NULL
,	NULL
D.	NULL
(	NULL
1978	NULL
)	NULL
Am	NULL
.	NULL

J.	NULL
Physiol	NULL
.	NULL

4	NULL
,	NULL
E97-E102	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
/810-0q	NULL
[	NULL
'mmmy/	NULL
:	NULL
dyy	NULL
wo	NULL
;	NULL
popeoumog	NULL
Purification	NULL
and	NULL
Characterization	NULL
of	NULL
the	NULL
Human	NULL
SR	NULL
31747A-binding	NULL
Protein	NULL
:	NULL
A	NULL
NUCLEAR	NULL
MEMBRANE	NULL
PROTEIN	NULL
RELATED	NULL
TO	NULL
YEAST	NULL
STEROL	NULL
ISOMERASE	NULL
Omar	NULL
Jbilo	NULL
,	NULL
Hubert	NULL
Vidal	NULL
,	NULL
Raymond	NULL
Paul	NULL
,	NULL
Nathalie	NULL
De	NULL
Nys	NULL
,	NULL
Mohammed	NULL
Bensaid	NULL
,	NULL
Sandra	NULL
Silve	NULL
,	NULL
Pierre	NULL
Carayon	NULL
,	NULL
Danielle	NULL
Davi	NULL
,	NULL
Sylvaine	NULL
Gali¢égue	NULL
,	NULL
Bernard	NULL
Bourrié	NULL
,	NULL
Jean-Claude	NULL
Guillemot	NULL
,	NULL
Pascual	NULL
Ferrara	NULL
,	NULL
Gérard	NULL
Loison	NULL
,	NULL
Jean-Pierre	NULL
Maffrand	NULL
,	NULL
Gérard	NULL
Le	NULL
Fur	NULL
and	NULL
Pierre	NULL
Casellas	NULL
J.	NULL
Biol	NULL
.	NULL

Chem	NULL
.	NULL

1997	NULL
,	NULL
272:27107-27115.	NULL
doi	NULL
:	NULL
10.1074/jb0.272.43.27107	NULL
Access	NULL
the	NULL
most	NULL
updated	NULL
version	NULL
of	NULL
this	NULL
article	NULL
at	NULL
http	NULL
:	NULL
/www.jbe.org/content/272/43/27107	NULL
Alerts	NULL
:	NULL
«	NULL
When	NULL
this	NULL
article	NULL
is	NULL
cited	NULL
«	NULL
When	NULL
a	NULL
correction	NULL
for	NULL
this	NULL
article	NULL
is	NULL
posted	NULL
Click	NULL
here	NULL
to	NULL
choose	NULL
from	NULL
all	NULL
of	NULL
JBC	NULL
's	NULL
e-mail	NULL
alerts	NULL
This	NULL
article	NULL
cites	NULL
39	NULL
references	NULL
,	NULL
13	NULL
of	NULL
which	NULL
can	NULL
be	NULL
accessed	NULL
free	NULL
at	NULL
http	NULL
:	NULL
//www	NULL
610Z	NULL
'01	NULL
Aepy	NULL
uo	NULL
4g	NULL
wo	NULL
;	NULL
popeoumog	NULL

